0001104659-22-026319.txt : 20220224 0001104659-22-026319.hdr.sgml : 20220224 20220224063128 ACCESSION NUMBER: 0001104659-22-026319 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220222 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220224 DATE AS OF CHANGE: 20220224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 22666390 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 tm227491d1_8k.htm FORM 8-K
0001739104 false 12/31 0001739104 2022-02-22 2022-02-22 0001739104 us-gaap:CommonStockMember 2022-02-22 2022-02-22 0001739104 elan:TangiblePercentEquityUnitsMember 2022-02-22 2022-02-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): February 22, 2022

 

Elanco Animal Health Incorporated

(Exact name of registrant as specified in its charter)

 

Indiana  001-38661  82-5497352

(State or other jurisdiction

of incorporation)

  (Commission
File Number)
 

(I.R.S. Employer

Identification No.)

 

2500 Innovation Way

Greenfield, Indiana

(Address of principal executive offices)

 

46140

(Zip Code)

 

Registrant’s telephone number, including area code: (877) 352-6261

 

Not Applicable

(Former Name or Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which

registered

Common stock, no par value   ELAN   New York Stock Exchange
5.00% Tangible Equity Units   ELAT   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

¨  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 2.02Results of Operation and Financial Condition.

 

Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 24, 2022, announcing the results of operations for the full year and fiscal quarter ended December 31, 2021 and guidance for the full year and first quarter of 2022, for Elanco Animal Health Incorporated (the “Company”).

 

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

 

Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

As announced in early January 2022, the Board of Directors (the “Board”) of the Company, upon the recommendation of its Nominating and Corporate Governance Committee, resolved to move forward with eliminating supermajority voting rights in the Company’s governing documents and to implement new “proxy access” provisions.

 

As an implementing step, on February 22, 2022, the Board amended and restated the Company’s Bylaws (the “Bylaws”) to implement a proxy access bylaw permitting a shareholder, or a group of up to 20 shareholders, owning 3% or more of the Company’s outstanding common stock continuously for at least three years, to nominate, and have included in the Company’s proxy materials, director nominees constituting up to two individuals or 20% of the board (whichever is greater), provided that the shareholder(s) and the proxy access nominee(s) satisfy the requirements and the procedures set forth in the Bylaws.

 

The description of the amendments to the Bylaws is qualified in its entirety by reference to the text of the Bylaws, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
3.1   Elanco Animal Health Incorporated Amended and Restated Bylaws, effective February 22, 2022.
99.1   Press Release issued by Elanco Animal Health Incorporated, dated February 24, 2022.
104.1   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Elanco Animal Health Incorporated
   
Date: February 24, 2022 By: /s/ Todd Young
    Name:  Todd Young
    Title:  Executive Vice President and Chief Financial Officer

 

 

 

EX-3.1 2 tm227491d1_ex3-1.htm EXHIBIT 3.1

 

Exhibit 3.1

 

ELANCO ANIMAL HEALTH
INCORPORATED


AMENDED AND RESTATED BYLAWS


Adopted as of

February 22, 2022

(Effective February 22, 2022)

 

 

 

 

 

 

ELANCO ANIMAL HEALTH INCORPORATED

AMENDED AND RESTATED BYLAWS

 

INDEX

Page

 

Article I The Shareholders 1
Section 1.1.   Annual Meetings 1
Section 1.2.   Special Meetings 1
Section 1.3.   Time, Place, and Conduct of Meetings 1
Section 1.4.   Notice of Meetings 1
Section 1.5.   Quorum 1
Section 1.6.   Voting 1
Section 1.7.   Voting Lists 2
Section 1.8.   Fixing of Record Date 2
Section 1.9.   Notice of Shareholder Business 2
Section 1.10. Notice of Shareholder Nominees 4
Section 1.11. Inclusion of Shareholder Director Nominations in the Corporation’s Proxy Materials 6
Article II Board of Directors 12
Section 2.1.   General Powers 12
Section 2.2.   Number and Qualifications 12
Section 2.3.   Classes of Directors and Terms 13
Section 2.4.   Election of Directors 13
Section 2.5.   Meetings of Directors 13
Section 2.6.   Quorum and Manner of Acting 14
Section 2.7.   Resignations 14
Section 2.8.   Removal of Directors 14
Section 2.9.   Action without a Meeting 14
Section 2.10. Chairman of the Board of Directors 14
Section 2.11. Committees 14
Section 2.12.  Transactions with Corporation 14
Section 2.13. Compensation of Directors 15
Article III Officers 15
Section 3.1.   Chief Executive Officer 15
Section 3.2.   Chief Financial Officer 15
Section 3.3.   Secretary and Assistant Secretaries 15
Section 3.4.   Treasurer 15
Section 3.5.   Other Officers 16
Section 3.6.   Term of Office 16
Section 3.7.   Resignation 16
Section 3.8.   Removal 16
Section 3.9.   Vacancies 16

 

i

 

 

Article IV Execution of Instruments and Deposit of Corporate Funds 16
Section 4.1.   Execution of Instruments Generally 16
Section 4.2.   Notes, Checks, Other Instruments 16
Section 4.3.   Proxies 17
Article V Shares 17
Section 5.1.   Certificates for Shares 17
Section 5.2.   Transfer of Shares 17
Section 5.3.   Regulations 17
Section 5.4.   Transfer Agents and Registrars 18
Section 5.5.   Lost or Destroyed Certificates 18
Article VI Indemnification 18
Section 6.1.   Right to Indemnification 18
Section 6.2.   Insurance, Contracts and Funding 18
Section 6.3.   Non-Exclusive Rights; Applicability to Certain Proceedings 19
Section 6.4.   Advancement of Expenses 19
Section 6.5.   Procedures; Presumptions and Effect of Certain Proceedings; Remedies 19
Section 6.6.   Certain Definitions 21
Section 6.7.   Indemnification of Agents 21
Section 6.8.   Effect of Amendment or Repeal 21
Section 6.9.   Severability 21
Article VII Miscellaneous 21
Section 7.1.   Corporate Seal 21
Section 7.2.   Fiscal Year 21
Section 7.3.   Exclusive Forum 21

 

-ii

 

 

AMENDED AND RESTATED BYLAWS
of
ELANCO ANIMAL HEALTH INCORPORATED
(an Indiana Corporation)

 

Article I

The Shareholders

 

Section 1.1.          Annual Meetings. The annual meeting of the shareholders of the Corporation for the election of directors and for the transaction of such other business as properly may come before the meeting shall be held on such date and at such time as shall be designated by resolution of the Board of Directors from time to time. Failure to hold an annual meeting of the shareholders at such designated time shall not affect otherwise valid corporate acts or work a forfeiture or dissolution of the Corporation. The Chairman or the Board of Directors may postpone, reschedule or cancel any annual meeting previously called by the Board of Directors.

 

Section 1.2.          Special Meetings. Special meetings of the shareholders may be called at any time only by the Board of Directors or the Chairman of the Board of Directors. The Chairman or the Board of Directors may postpone, reschedule or cancel any special meeting previously called by the Board of Directors or the Chairman.

 

Section 1.3.          Time, Place, and Conduct of Meetings. Subject to Section 1.1, each meeting of the shareholders shall be held at such time of day and at such place or no place, solely by means of remote communication, as may be fixed by the Board of Directors, either within or without the State of Indiana, as shall be determined by the Board of Directors. Each adjourned meeting of the shareholders shall be held at such time and place as may be provided in the motion for adjournment. The chairman of each meeting shall have sole authority to decide questions relating to the conduct of that meeting.

 

Section 1.4.          Notice of Meetings. The Secretary shall cause a written or printed notice of the place, day and hour and the purpose or purposes of each meeting of the shareholders to be delivered or mailed (which may include by facsimile or other form of electronic communication) at least ten (10) but not more than sixty (60) days prior to the meeting, to each shareholder of record entitled to vote at the meeting, at the shareholder’s address as the same appears on the records maintained by the Corporation. Notice of any such shareholders meeting may be waived by any shareholder by delivering a written waiver to the Secretary before or after such meeting. Attendance at any meeting in person or by proxy when the instrument of proxy sets forth in reasonable detail the purpose or purposes for which the meeting is called, shall constitute a waiver of notice thereof. Notice of any adjourned meeting of the shareholders of the Corporation shall not be required to be given unless otherwise required by statute.

 

Section 1.5.          Quorum. At any meeting of the shareholders, a majority of the outstanding shares entitled to vote on a matter at such meeting, represented in person or by proxy, shall constitute a quorum for action on that matter. In the absence of a quorum, the chairman of the meeting or the holders of a majority of the shares entitled to vote present in person or by proxy or if no shareholder entitled to vote is present in person or by proxy any officer entitled to preside at or act as Secretary of such meeting, may adjourn such meeting from time to time, until a quorum shall be present. At any such adjourned meeting at which a quorum may be present, any business may be transacted which might have been transacted at the meeting as originally called.

 

Section 1.6.          Voting. Except as otherwise provided by statute or by the Articles of Incorporation of the Corporation (as amended, restated or otherwise modified from time to time, the “Articles of Incorporation”), at each meeting of the shareholders each holder of shares entitled to vote shall have the right to one vote for each share standing in the shareholder’s name on the books of the Corporation on the record date fixed for the meeting under Section 1.8. Each shareholder entitled to vote shall be entitled to vote in person or by proxy executed in writing (which shall include facsimile) or transmitted by electronic submission by the shareholder or a duly authorized attorney in fact. Unless otherwise specified in the Articles of Incorporation or by applicable statute, the vote of shareholders approving any matter, other than the election of directors, shall require that the votes cast in favor of the matter exceed the votes cast opposing the matter at a meeting at which a quorum is present. In the event that more than one group of shares is entitled to vote as a separate voting group, the vote of each group shall be considered and decided separately. Directors shall be elected by a plurality of the votes properly cast, as set forth in Article 13 of the Articles of Incorporation.

 

 

 

 

Section 1.7.          Voting Lists. The Secretary shall make or cause to be made, after a record date for a meeting of shareholders has been fixed under Section 1.8 and at least five (5) days before such meeting, a complete list of the shareholders entitled to vote at such meeting, arranged in alphabetical order, with the address of each such shareholder and the number of shares so entitled to vote held by each. The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be on file at the principal office of the Corporation and subject to inspection on written demand by any shareholder entitled to vote at the meeting; provided that (i) the shareholder’s demand is made in good faith for a proper purpose; (ii) the shareholder describes with reasonable particularity the shareholder’s purpose; and (iii) the list is directly connected with the shareholder’s purpose. Such list shall be produced and kept open at the time and place of the meeting and subject to the inspection of any such shareholder during the holding of such meeting or any adjournment. Except as otherwise required by law, such list shall be the only evidence as to who are the shareholders entitled to vote at any meeting of the shareholders. In the event that more than one group of shares is entitled to vote as a separate voting group at the meeting, there shall be a separate listing of the shareholders of each group.

 

Section 1.8.          Fixing of Record Date. For the purpose of determining shareholders entitled to notice of or to vote at any meeting of shareholders or any adjournment thereof, or entitled to receive payment of any dividend, or in order to make a determination of shareholders for any other proper purpose, the Board of Directors shall fix in advance a date as the record date for any such determination of shareholders, not more than seventy (70) days prior to the date on which the particular action requiring this determination of shareholders is to be taken. When a determination of shareholders entitled to vote at any meeting of shareholders has been made as provided in this section, the determination shall, to the extent permitted by law, apply to any adjournment thereof.

 

Section 1.9.          Notice of Shareholder Business.

 

(a)                 At an annual meeting of the shareholders, the only items of business that shall be conducted are those which are proper subjects for action by the shareholders under Indiana law and which have been properly brought before the meeting. To be properly brought before an annual meeting, business must be (i) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors, (ii) otherwise properly brought before the meeting by or at the direction of the Board of Directors, or (iii) otherwise properly brought before the meeting by a shareholder in accordance with this Section 1.9. Except for proposals properly made in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (as so amended and inclusive of such rules and regulations, the “Exchange Act”), and included in the notice of meeting given by or at the direction of the Board of Directors, the foregoing clause (iii) shall be the exclusive means by which a shareholder may propose business to be brought before the meeting. For any item of business (other than nomination of a person for election as a director which is subject to Section 1.10) to be properly brought before an annual meeting by a shareholder, the shareholder proposing the item of business (a “proposing shareholder”) must (A) be a record owner of shares of the Corporation’s common stock both at the time of giving the notice provided for in this Section 1.9 and at the time of the meeting, (B) be entitled to vote at the meeting, (C) have the legal right and authority to make the proposal for consideration at the meeting, (D) have given a notice which is timely as required by subsection (b) and in proper form as required by subsection (c), and (E) appear at the meeting in person or by a designated representative to present the item of business.

 

(b)                To be timely, a proposing shareholder’s notice must be delivered to or mailed and received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the date that is no less than ninety (90) calendar days nor more than one hundred twenty (120) calendar days in advance of the anniversary date of the Corporation’s last annual meeting of shareholders; provided, however, that in the event that no annual meeting was held in the previous year or the date of the annual meeting has been changed by more than thirty (30) days from the anniversary date of the Corporation’s last annual meeting of shareholders, notice by the proposing shareholder to be timely must be so received not later than the close of business on the later of one hundred twenty (120) calendar days in advance of such annual meeting or, if later, ten (10) calendar days following the date on which public disclosure of the date of the meeting is first made. For purposes of this Section 1.9 and Section 1.10, “public disclosure” means disclosure in a press release reported by a national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14, or 15(d) of the Exchange Act. No adjournment or postponement of an annual meeting or announcement thereof shall commence a new time period for the giving of a timely notice as described above.

 

2

 

 

(c)                 To be in proper form, a proposing shareholder’s notice to the Secretary shall set forth (i) the name and record address of the proposing shareholder(s); (ii) the class and number of the Corporation’s shares which are beneficially owned by the proposing shareholder(s) and Shareholder Associated Persons (as defined below); (iii) a brief description of any derivative instrument (as defined in IND. CODE §23-1-20-6.5 as in effect on August 8, 2019) or other agreement, arrangement, or understanding (including any swaps, warrants, short positions, profits interests, options, hedging transactions, or borrowed or loaned shares) with respect to the Corporation’s shares, engaged in, directly or indirectly by the proposing shareholder(s) and Shareholder Associated Persons, where the purpose or effect of such instrument, agreement, arrangement or understanding is to increase or decrease such shareholders’ or Shareholder Associated Persons’ ability to share in the profits derived from any increase in the value of the Corporation’s shares, mitigate economic exposure to changes in value of the shares, and/or increase or decrease the voting power of such shareholder(s) or Shareholder Associated Person(s); and (iv) as to each item of business being proposed (A) a brief description of the business to be brought before the annual meeting; (B) the reasons for conducting such business at the annual meeting; (C) the text of the proposal or business (including the text of any resolutions or amendments to the Articles of Incorporation or these Bylaws proposed for consideration); (D) any material interest of the proposing shareholder(s) and Shareholder Associated Persons in such business; (E) a brief description of all agreements, arrangements or understandings between or among the proposing shareholder(s) and Shareholder Associated Person(s) or between or among any proposing shareholder or Shareholder Associated Person and any other person or entity in connection with such business; (F) a representation whether the proposing shareholder or Shareholder Associated Person intends to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation’s outstanding shares required to approve the proposal and/or otherwise to solicit proxies from shareholders in support of the proposal; and (G) any other information relating to each such person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with the solicitation of proxies by each such person with respect to the proposed business to be brought by each such person before the annual meeting pursuant to Section 14 of the Exchange Act, and the rules and regulations promulgated thereunder. For purposes of this Section 1.9 and Section 1.10, the term “beneficial ownership” shall have the meaning specified in IND. CODE §23-1-20-3.5 as in effect on August 8, 2019, and the term “Shareholder Associated Person” of any shareholder means (i) any person controlling, directly or indirectly, or acting in concert with, such shareholder, (ii) any beneficial owner of shares of stock of the Corporation owned of record or beneficially by such shareholder and on whose behalf the proposal or nomination, as applicable, is made, and (iii) any person controlling, controlled by or under common control with, or acting in concert with, any such person referred to in the preceding clauses (i) and (ii).

 

(d)                A proposing shareholder shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in the notice shall be true, correct and complete in all material respects (i) as of the record date for the meeting and (ii) as of the date that is ten (10) business days prior to the meeting or any adjournment thereof. Such updates shall be delivered to or mailed and received by the Secretary at the principal executive offices of the Corporation (A) in the case of the update required under subsection (i), not later than five (5) business days after the record date, and (B) in the case of the update required under subsection (ii), not later than seven (7) business days prior to the meeting or any adjournment thereof.

 

(e)                 No business shall be conducted at any annual meeting of shareholders except in accordance with the procedures set forth in this Section 1.9. The chairman of an annual meeting shall, if the facts warrant, determine and declare to the meeting that business was not properly brought before the meeting in accordance with the provisions of this Section 1.9, and if the chairman should so determine, he or she shall so declare to the meeting any such business not properly brought before the meeting shall not be transacted, notwithstanding that proxies may have been solicited in respect of such business.

 

(f)                  The requirements of this Section 1.9 shall apply to any item of business to be brought before a meeting of shareholders (other than the election of directors and any proposal properly made pursuant to Rule 14a-8 of the Exchange Act) regardless of whether the business is presented to shareholders directly at the meeting or by means of an independently financed proxy solicitation. The requirements of this Section 1.9 are included to provide the Corporation notice of a shareholder’s intention to bring business before a meeting and shall not be construed as imposing upon any shareholder the requirement to seek approval from the Corporation as a condition precedent to bringing any such business before a meeting. Notwithstanding the foregoing provisions of this Section 1.9, a shareholder shall also comply with all applicable requirements of the Exchange Act with respect to business to be brought before a meeting of shareholders that is subject to this Section 1.9; provided, however, that any references in these Bylaws to the Exchange Act or the rules promulgated thereunder are not intended to and shall not limit the requirements applicable to business to be brought before a meeting of shareholders pursuant to these Bylaws.

 

(g)                At any special meeting of the shareholders, only such business shall be conducted as shall have been brought before the meeting by or at the direction of the Board of Directors or the Chairman of the Board of Directors.

 

3

 

 

Section 1.10.      Notice of Shareholder Nominees.

 

(a)                 Only persons who are nominated by or at the direction of the Board of Directors or by shareholders in accordance with the procedures set forth in this Section 1.10 shall be eligible for election as Directors, except as may be otherwise provided in the Articles of Incorporation with respect to the right of holders of preferred stock of the Corporation to nominate and elect a specified number of directors in certain circumstances. Nominations of persons for election to the Board of Directors in accordance with this Section 1.10 may be made (i) at or prior to a meeting of shareholders by or at the direction of the Board of Directors or by any nominating committee or person appointed by or at the direction of the Board of Directors, and (ii) at an annual meeting of shareholders or a special meeting of shareholders (but only if the election of Directors is a matter specified in the notice of special meeting) by any shareholder entitled to vote for the election of Directors at the meeting who complies with the notice procedures set forth in this Section 1.10 (a “nominating shareholder”). Such nominations shall be made pursuant to a notice which is timely as required by subsection (b) and in proper form as required by subsection (c) and any person proposed to be nominated (a “proposed nominee”) must be eligible for election as required by subsection (e).

 

(b)                To be timely, a nominating shareholder’s notice, if it relates to an annual meeting of shareholders, must be delivered to or mailed and received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the date that is not less than ninety (90) calendar days nor more than one hundred twenty (120) calendar days in advance of the anniversary date of the Corporation’s last annual meeting of shareholders; provided, however, that in the event that no annual meeting was held in the previous year or the date of the annual meeting has been changed by more than thirty (30) days from the anniversary date of the Corporation’s last annual meeting of shareholders, notice by the nominating shareholder to be timely must be so received not later than the close of business on the later of one hundred twenty (120) calendar days in advance of such annual meeting or, if later, ten (10) calendar days following the date on which public disclosure of the date of the meeting is first made. No adjournment or postponement of an annual meeting or announcement thereof shall commence a new time period for the giving of a timely notice as described above. If the nominating shareholder notice of a proposed nominee relates to a special meeting of shareholders at which directors are to be elected pursuant to the Corporation’s notice of meeting, it must be delivered to or mailed and received by the Secretary of the Corporation at the principal executive offices of the Corporation not less than ninety (90) calendar days in advance of the date of the special meeting, or, if later, the tenth (10th) calendar day after public disclosure of the date of the special meeting is made.

 

(c)                 To be in proper form for purposes of this Section 1.10, a nominating shareholder’s notice shall set forth: (i) the name and record address of the nominating shareholder(s) and their Shareholder Associated Person(s) (ii) the class and number of the Corporation’s shares which are beneficially owned by the nominating shareholder(s) and the Shareholder Associated Person(s), (iii) a brief description of any derivative instrument (as defined in Section 1.9(c)(iii)) or any other agreement, arrangement, or understanding engaged in, directly or indirectly, by the nominating shareholder(s) and the Shareholder Associated Person(s) with respect to the Corporation’s shares, (iv) as to each proposed nominee, (A) the proposed nominee’s name, age, business address and residence address; (B) the proposed nominee’s principal occupation or employment; (C) the class and number of the Corporation’s shares which are beneficially owned by the proposed nominee; (D) a brief description of any derivative instrument (as defined in Section 1.9(c)(iii)) or any other agreement, arrangement, or understanding engaged in, directly or indirectly, by the proposed nominee with respect to the Corporation’s shares; (E) a brief description of all material agreements, arrangements, understandings or relationships, including all direct or indirect compensatory arrangements, between or among the proposed nominee, the nominating shareholder(s) or any of the Shareholder Associated Person(s); (F) a representation whether the nominating shareholder or any of the Shareholder Associated Person(s) intends to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation’s outstanding shares required to elect the proposed nominee and/or otherwise to solicit proxies from shareholders in support of the nomination; and (G) any other information relating to the proposed nominee that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Section 14 of the Exchange Act (including without limitation the proposed nominee’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected).

 

4

 

 

 

(d)                A nominating shareholder shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in the notice shall be true, correct and complete in all material respects (i) as of the record date for the meeting and (ii) as of the date that is ten (10) business days prior to the meeting or any adjournment thereof. Such updates shall be delivered to or mailed and received by the Secretary at the principal executive offices of the Corporation (A) in the case of the update required under subsection (i), not later than five (5) business days after the record date, and (B) in the case of the update required under subsection (ii), not later than seven (7) business days prior to the meeting or any adjournment thereof.

 

(e)                 To be eligible as a director of the Corporation, a proposed nominee must deliver (in accordance with the time periods prescribed for delivery of notice under paragraph (b) of this Section 1.10) to the Secretary at the principal executive offices of the Corporation a written questionnaire with respect to the background and qualification of the proposed nominee, including without limitation as to the independence of the proposed nominee (which questionnaire shall be provided by the Secretary upon written request) and a written representation and agreement (in the form provided by the Secretary upon written request) that the proposed nominee (i) is not and will not become a party to (A) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a “voting commitment”) that has not been disclosed to the Corporation or (B) any voting commitment that could limit or interfere with such person’s ability to comply, if elected as a director of the Corporation, with such person’s fiduciary duties under applicable law, (ii) is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed therein, and (iii) agrees, if elected, to serve as a member of the Board of Directors for the entire term and would be in compliance, if elected as a director of the Corporation, and will comply with all applicable codes of conduct, corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the Corporation and other guidelines and policies applicable to members of the Board of Directors.

 

(f)                  The Corporation may require any proposed nominee to furnish such other information (i) as may reasonably be required by the Corporation to determine the eligibility of such proposed nominee to serve as an independent director of the Corporation under applicable listing rules or (ii) that could be material to a reasonable shareholder’s understanding of the independence or lack of independence of such proposed nominee.

 

(g)                The chairman of the meeting may, if the facts warrant, determine and declare to the meeting that a nomination was not so declared in accordance with the procedures prescribed by these Bylaws, and if the chairman should so determine, he or she shall so declare to the meeting and the defective nomination shall be disregarded, notwithstanding that proxies in respect of such nomination may have been received by the Corporation. The requirements of this Section 1.10 are included to provide the Corporation notice of a shareholder’s intention to nominate a proposed nominee and shall not be construed as imposing upon any shareholder the requirement to seek approval from the Corporation as a condition precedent to nominating any such proposed nominee for a meeting of shareholders. Notwithstanding the foregoing provisions of this Section 1.10, a shareholder shall also comply with all applicable requirements of the Exchange Act with respect to the nomination of any director that is subject to this Section 1.10; provided, however, that any references in these Bylaws to the Exchange Act or the rules promulgated thereunder are not intended to and shall not limit the requirements applicable to nominations to be considered pursuant to these Bylaws. Nothing in this Section 1.10 shall be deemed to affect any rights of the holders of any series of preferred stock of the Corporation to elect directors pursuant to any applicable provisions of the Articles of Incorporation.

 

5 

 

 

Section 1.11.      Inclusion of Shareholder Director Nominations in the Corporation’s Proxy Materials. Subject to the terms and conditions set forth in these Bylaws, the Corporation shall include in its proxy materials for an annual meeting of shareholders the name, together with the Required Information (as defined below), of any person nominated for election (the “Shareholder Nominee”) to the Board of Directors by a shareholder or group of shareholders that satisfy the requirements of this Section 1.11, including qualifying as an Eligible Shareholder (as defined in paragraph (D) below) and that expressly requests at the time of providing the written notice required by this Section 1.11 (a “Proxy Access Notice”) to have its nominee included in the Corporation’s proxy materials pursuant to this Section 1.11. For the purposes of this Section 1.11:

 

(1) “Voting Stock” shall mean outstanding shares of capital stock of the Corporation entitled to vote generally for the election of Directors;

 

(2) “Constituent Holder” shall mean any shareholder, collective investment fund included within a Qualifying Fund (as defined in paragraph (E) below) or beneficial holder whose share ownership is counted for the purposes of qualifying as holding the Proxy Access Request Required Shares (as defined in paragraph (E) below) or qualifying as an Eligible Shareholder (as defined in paragraph (E) below);

 

(3) “affiliate” and “associate” shall have the meanings ascribed thereto in Rule 405 under the Securities Act of 1933; provided, however, that the term “partner” as used in the definition of “associate” shall not include any limited partner that is not involved in the management of the relevant partnership; and

 

(4) a shareholder (including any Constituent Holder) shall be deemed to “own” only those outstanding shares of Voting Stock as to which the shareholder itself (or such Constituent Holder itself) possesses both (a) the full voting and investment rights pertaining to the shares and (b) the full economic interest in (including the opportunity for profit and risk of loss on) such shares. The number of shares calculated in accordance with the foregoing clauses (a) and (b) shall be deemed not to include (and to the extent any of the following arrangements have been entered into by affiliates of the shareholder (or of any Constituent Holder), shall be reduced by) any shares (x) sold by such shareholder or Constituent Holder (or any of either’s affiliates) in any transaction that has not been settled or closed, including any short sale, (y) borrowed by such shareholder or Constituent Holder (or any of either’s affiliates) for any purposes or purchased by such shareholder or Constituent Holder (or any of either’s affiliates) pursuant to an agreement to resell, or (z) subject to any option, warrant, forward contract, swap, contract of sale, other derivative or similar agreement entered into by such shareholder or Constituent Holder (or any of either’s affiliates), whether any such instrument or agreement is to be settled with shares or with cash based on the notional amount or value of Voting Stock, in any such case which instrument or agreement has, or is intended to have, or if exercised by either party thereto would have, the purpose or effect of (i) reducing in any manner, to any extent or at any time in the future, such shareholder’s or Constituent Holder’s (or either’s affiliate’s) full right to vote or direct the voting of any such shares, and/or (ii) hedging, offsetting or altering to any degree gain or loss arising from the full economic ownership of such shares by such shareholder or Constituent Holder (or either’s affiliate), other than any such arrangements solely involving an exchange listed multi-industry market index fund in which Voting Stock represents at the time of entry into such arrangement less than 10% of the proportionate value of such index. A shareholder (including any Constituent Holder) shall “own” shares held in the name of a nominee or other intermediary so long as the shareholder itself (or such Constituent Holder itself) retains the right to instruct how the shares are voted with respect to the election of Directors and the right to direct the disposition thereof and possesses the full economic interest in the shares. A shareholder’s (including any Constituent Holder’s) ownership of shares shall be deemed to continue during any period (i) in which shares have been loaned in the ordinary course of business if the person claiming ownership may recall such loaned shares on no more than three business days’ notice and has recalled such loaned shares as of the date of the Proxy Access Notice and holds such shares through the date of the annual meeting of shareholders or (ii) any voting power over such shares has been delegated by means of a proxy, power of attorney or other instrument or arrangement which in all such cases is revocable at any time by the shareholder. The terms “owned,” “owning” and other variations of the word “own” shall have correlative meanings.

 

(a)           For purposes of this Section 1.11, the “Required Information” that the Corporation will include in its proxy statement is (1) the information concerning the Shareholder Nominee and the Eligible Shareholder that the Corporation determines is required to be disclosed in the Corporation’s proxy statement by the regulations promulgated under the Exchange Act; and (2) if the Eligible Shareholder so elects, a Statement (as defined in paragraph (F) below). The Corporation shall also include the name of the Shareholder Nominee in its proxy card. For the avoidance of doubt, and any other provision of these Bylaws notwithstanding, the Corporation may in its sole discretion solicit against, and include in the proxy statement its own statements or other information relating to, any Eligible Shareholder and/or Shareholder Nominee, including any information provided to the Corporation with respect to the foregoing.

 

6 

 

 

(b)           To be timely, a shareholder’s Proxy Access Notice must be delivered to or mailed and received by the Secretary at the principal executive offices of the Corporation within the time periods applicable to shareholder notices of nominations pursuant to Section 1.10 of these Bylaws. In no event shall any adjournment or postponement of an annual meeting, the date of which has been announced by the Corporation, commence a new time period for the giving of a Proxy Access Notice.

 

(c)           The number of Shareholder Nominees (including Shareholder Nominees that were submitted by an Eligible Shareholder for inclusion in the Corporation’s proxy materials pursuant to this Section 1.11 but either are subsequently withdrawn or that the Board of Directors decides to nominate as Board of Directors’ nominees or otherwise appoint to the Board of Directors) appearing in the Corporation’s proxy materials with respect to an annual meeting of shareholders shall not exceed the greater of (rounded down to the nearest whole number) (x) two (2) and (y) the largest whole number that does not exceed 20% of the number of directors in office as of the last day on which a Proxy Access Notice may be delivered in accordance with the procedures set forth in this Section 1.11 (such greater number, the “Permitted Number”); provided, however, that the Permitted Number shall not exceed the number of directors to be elected at such annual meeting and the Permitted Number shall be reduced by:

 

(1)                the number of directors in office or director candidates that in either case will be included in the Corporation’s proxy materials with respect to such annual meeting as an unopposed (by the Corporation) nominee pursuant to any agreement, arrangement or other understanding with any shareholder or group of shareholders (other than any such agreement, arrangement or understanding entered into in connection with an acquisition of Voting Stock, by such shareholder or group of shareholders, from the Corporation), other than any such director referred to in this clause (1) who at the time of such annual meeting will have served as a director continuously, as a nominee of the Board of Directors, for at least two (2) annual meetings, but only to the extent the Permitted Number after such reduction with respect to this clause (1) equals or exceeds one; and

 

(2)                the number of directors in office that will be included in the Corporation’s proxy materials with respect to such annual meeting for whom access to the Corporation’s proxy materials was previously provided pursuant to this Section 1.11, other than any such director referred to in this clause (2) who at the time of such annual meeting will have served as a director continuously, as a nominee of the Board of Directors, for at least two (2) annual meetings;

 

provided, further, that in the event the Board of Directors resolves to reduce the size of the Board of Directors effective on or prior to the date of the annual meeting, the Permitted Number shall be calculated based on the number of directors in office as so reduced. In the event that the number of Shareholder Nominees submitted by Eligible Shareholders pursuant to this Section 1.11 exceeds the Permitted Number, each Eligible Shareholder will select one Shareholder Nominee for inclusion in the Corporation’s proxy materials until the Permitted Number is reached, going in order of the amount (largest to smallest) of shares of Voting Stock each Eligible Shareholder disclosed as owned in its Proxy Access Notice submitted to the Corporation. If the Permitted Number is not reached after each Eligible Shareholder has selected one (1) Shareholder Nominee, this selection process will continue as many times as necessary, following the same order each time, until the Permitted Number is reached.

 

(d)          An “Eligible Shareholder” is one or more shareholders of record who own and have owned, or are acting on behalf of one or more beneficial owners who own and have owned (in each case as defined above), in each case continuously for at least three (3) years as of both the date that the Proxy Access Notice is received by the Corporation pursuant to this Section 1.11, and as of the record date for determining shareholders eligible to vote at the annual meeting, at least three percent (3%) of the aggregate voting power of the Voting Stock (the “Proxy Access Request Required Shares”), and who continue to own the Proxy Access Request Required Shares at all times between the date such Proxy Access Notice is received by the Corporation and the date of the applicable annual meeting, provided that the aggregate number of shareholders, and, if and to the extent that a shareholder is acting on behalf of one or more beneficial owners, of such beneficial owners, whose share ownership is counted for the purpose of satisfying the foregoing ownership requirement shall not exceed twenty (20). Two or more collective investment funds that are (I) part of the same family of funds and sponsored by the same employer or (II) a “group of investment companies” as such term is defined in Section 12(d)(1)(G)(ii) of the Investment Company Act of 1940 (each of the foregoing, a “Qualifying Fund”) shall be treated as one shareholder for the purpose of determining the aggregate number of shareholders in this paragraph (D), provided that each fund included within a Qualifying Fund otherwise meets the requirements set forth in this Section 1.11. No shares may be attributed to more than one group constituting an Eligible Shareholder under this Section 1.11 (and, for the avoidance of doubt, no shareholder may be a member of more than one group constituting an Eligible Shareholder). A record holder acting on behalf of one or more beneficial owners will not be counted separately as a shareholder with respect to the shares owned by beneficial owners on whose behalf such record holder has been directed in writing to act, but each such beneficial owner will be counted separately, subject to the other provisions of this paragraph (D), for purposes of determining the number of shareholders whose holdings may be considered as part of an Eligible Shareholder’s holdings. For the avoidance of doubt, Proxy Access Request Required Shares will qualify as such if and only if the beneficial owner of such shares as of the date of the Proxy Access Notice has itself individually beneficially owned such shares continuously for the three-year (3 year) period ending on that date and through the other applicable dates referred to above (in addition to the other applicable requirements being met).

 

7 

 

 

(e)           No later than the final date when a nomination pursuant to this Section 1.11 may be timely delivered to the Corporation, an Eligible Shareholder (including each Constituent Holder) must provide the following information in writing to the Secretary of the Corporation:

 

(1)           with respect to each Constituent Holder, the name and address of, and number of shares of Voting Stock owned by, such person;

 

(2)           one or more written statements from the record holder of the shares (and from each intermediary through which the shares are or have been held during the requisite three-year (3 year) holding period) verifying that, as of a date within seven (7) calendar days prior to the date the Proxy Access Notice is delivered to the Corporation, such person owns, and has owned continuously for the preceding three (3) years, the Proxy Access Request Required Shares, and such person’s agreement to provide:

 

(i)                  within ten (10) days after the record date for the annual meeting, written statements from the record holder and intermediaries verifying such person’s continuous ownership of the Proxy Access Request Required Shares through the record date, together with any additional information reasonably requested to verify such person’s ownership of the Proxy Access Request Required Shares; and

 

(ii)                immediate notice if the Eligible Shareholder ceases to own any of the Proxy Access Request Required Shares prior to the date of the applicable annual meeting of shareholders;

 

(3)           any information relating to such Eligible Shareholder (including any Constituent Holder) and their respective affiliates or associates or others acting in concert therewith, and any information relating to such Eligible Shareholder’s Shareholder Nominee(s), in each case that would be required to be disclosed in a proxy statement and form of proxy or other filings required to be made in connection with solicitations of proxies for the election of such Shareholder Nominee(s) in a contested election pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder;

 

(4)           a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three (3) years, and any other material relationships, between or among the Eligible Shareholder (including any Constituent Holder) and its or their respective affiliates and associates, or others acting in concert therewith, on the one hand, and each of such Eligible Shareholder’s Shareholder Nominee(s), and his or her respective affiliates and associates, or others acting in concert therewith, on the other hand, including without limitation all information that would be required to be disclosed pursuant to Rule 404 promulgated under Regulation S-K if the Eligible Shareholder (including any Constituent Holder), or any affiliate or associate thereof or person acting in concert therewith, were the “registrant” for purposes of such rule and the Shareholder Nominee were a director or executive officer of such registrant;

 

8 

 

 

(5)           a representation that such person:

 

(i)                  acquired the Proxy Access Request Required Shares in the ordinary course of business and not with the intent to change or influence control of the Corporation, and does not presently have any such intent;

 

(ii)                has not nominated and will not nominate for election to the Board of Directors at the annual meeting any person other than the Shareholder Nominee(s) being nominated pursuant to this Section 1.11;

 

(iii)              has not engaged and will not engage in, and has not and will not be a “participant” in another person’s, “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act in support of the election of any individual as a director at the annual meeting other than its Shareholder Nominee(s) or a nominee of the Board of Directors;

 

(iv)               has not and will not distribute to any shareholder any form of proxy for the annual meeting other than the form distributed by the Corporation; and

 

(v)                has provided and will provide facts, statements and other information in all communications with the Corporation and its shareholders that are and will be true and correct in all material respects and do not and will not omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading, and has otherwise complied and will otherwise comply with all applicable laws, rules and regulations in connection with any actions taken pursuant to this Section 1.11;

 

(6)           in the case of a nomination by a group of shareholders that together is such an Eligible Shareholder, the designation by all group members of one group member that is authorized to act on behalf of all members of the nominating shareholder group with respect to the nomination and matters related thereto, including withdrawal of the nomination; and

 

(7)           an undertaking that such person agrees to:

 

(i)                  assume all liability stemming from, and indemnify and hold harmless the Corporation and each of its directors, officers, and employees individually against any liability, loss or damages in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative, against the Corporation or any of its directors, officers or employees arising out of any legal or regulatory violation arising out of the Eligible Shareholder’s communications with the shareholders of the Corporation or out of the information that the Eligible Shareholder (including such person) provided to the Corporation; and

 

(ii)                file with the Securities and Exchange Commission any solicitation by the Eligible Shareholder of shareholders of the Corporation relating to the annual meeting at which the Shareholder Nominee will be nominated.

 

(iii)              In addition, no later than the final date when a nomination pursuant to this Section 1.11 may be delivered to the Corporation, a Qualifying Fund whose share ownership is counted for purposes of qualifying as an Eligible Shareholder must provide to the Secretary of the Corporation documentation reasonably satisfactory to the Board of Directors that demonstrates that the funds included within the Qualifying Fund satisfy the definition thereof. In order to be considered timely, any information required by this Section 1.11 to be provided to the Corporation must be supplemented (by delivery to the Secretary of the Corporation) (1) no later than ten (10) days following the record date for the applicable annual meeting, to disclose the foregoing information as of such record date, and (2) no later than the fifth day before the annual meeting, to disclose the foregoing information as of the date that is no earlier than ten (10) days prior to such annual meeting. For the avoidance of doubt, the requirement to update and supplement such information shall not permit any Eligible Shareholder or other person to change or add any proposed Shareholder Nominee or be deemed to cure any defects or limit the remedies (including without limitation under these Bylaws) available to the Corporation relating to any defect.

 

9 

 

 

(f)            The Eligible Shareholder may provide to the Secretary of the Corporation, at the time the information required by this Section 1.11 is originally provided, a written statement for inclusion in the Corporation’s proxy statement for the annual meeting, not to exceed five hundred (500) words, in support of the candidacy of such Eligible Shareholder’s Shareholder Nominee (the “Statement”). Notwithstanding anything to the contrary contained in this Section 1.11, the Corporation may omit from its proxy materials any information or Statement that it, in good faith, believes:

 

(i)                  would violate any applicable law, rule, regulation or listing standard;

 

(ii)                is not true and correct in all material respects or omits to state a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading; or

 

(iii)              directly or indirectly impugns the character, integrity or personal reputation of, or directly or indirectly makes charges concerning improper, illegal or immoral conduct or associations, without factual foundation, with respect to any person.

 

(g)           No later than the final date when a nomination pursuant to this Section 1.11 may be delivered to the Corporation, each Shareholder Nominee must:

 

(i)            provide an executed agreement, in a form deemed satisfactory by the Board of Directors or its designee (which form shall be provided by the Corporation reasonably promptly upon written request of a shareholder), that such Shareholder Nominee:

 

(A)               consents to being named in the Corporation’s proxy statement and form of proxy card (and will not agree to be named in any other person’s proxy statement or form of proxy card) as a nominee and to serving as a director of the Corporation if elected;

 

(B)               agrees, if elected, to adhere to the Corporation’s Corporate Governance Guidelines any other Corporation policies and guidelines applicable to directors; and

 

(C)               is not and will not become a party to any compensatory, payment or other financial agreement, arrangement or understanding with any person or entity in connection with his or her nomination, service or action as a director of the Corporation, or any agreement, arrangement or understanding with any person or entity as to how the Shareholder Nominee would vote or act on any issue or question as a director, in each case that has not been disclosed to the Corporation;

 

(ii)                complete, sign and submit all questionnaires, representations and agreements required by these Bylaws or of the Corporation’s directors generally; and

 

(iii)              provide such additional information as necessary to permit the Board of Directors to determine if such Shareholder Nominee:

 

(A)               is independent under the listing standards of the New York Stock Exchange (“NYSE”), any applicable rules of the Securities and Exchange Commission and any publicly disclosed standards used by the Board of Directors in determining and disclosing the independence of the Corporation’s directors;

 

10 

 

 

(B)               has any direct or indirect relationship with the Corporation other than those relationships that have been deemed categorically immaterial pursuant to the standards used by the Corporation for determining director independence;

 

(C)               would, by serving on the Board of Directors, violate or cause the Corporation to be in violation of these Bylaws, the Corporation’s Articles of Incorporation, the rules and listing standards of the NYSE or any applicable law, rule or regulation; and

 

(D)               is or has been subject to any event specified in Item 401(f) of Regulation S-K (or successor rule) of the Securities and Exchange Commission.

 

(E)                In the event that any information or communications provided by the Eligible Shareholder (or any Constituent Holder) or the Shareholder Nominee to the Corporation or its shareholders ceases to be true and correct in all material respects or omits a material fact necessary to make the statements made, in light of the circumstances under which they were made, not misleading, each Eligible Shareholder or Shareholder Nominee, as the case may be, shall promptly notify the Secretary of the Corporation of any defect in such previously provided information and of the information that is required to correct any such defect; it being understood for the avoidance of doubt that providing any such notification shall not be deemed to cure any such defect or limit the remedies (including without limitation under these Bylaws) available to the Corporation relating to any such defect.

 

(h)          Any Shareholder Nominee who is included in the Corporation’s proxy materials for a particular annual meeting of shareholders but either (1) withdraws from or becomes ineligible or unavailable for election at that annual meeting (other than by reason of such Shareholder Nominee’s death or disability), or (2) does not receive votes cast in favor of the Shareholder Nominee’s election of at least twenty (20)% of the shares represented in person or by proxy at the annual meeting, will be ineligible to be a Shareholder Nominee pursuant to this Section 1.11 for the next two annual meetings. Any Shareholder Nominee who is included in the Corporation’s proxy statement for a particular annual meeting of shareholders, but subsequently is determined not to satisfy the eligibility requirements of this Section 1.11 or any other provision of these Bylaws, the Corporation’s Articles of Incorporation or other applicable regulation any time before the annual meeting of shareholders, will not be eligible for election at the relevant annual meeting of shareholders and no other nominee may be substituted by the Eligible Shareholder who nominated such Nominee.

 

(i)           The Corporation shall not be required to include, pursuant to this Section 1.11, a Shareholder Nominee in its proxy materials for any annual meeting of shareholders, or, if the proxy statement already has been filed, to allow the nomination of a Shareholder Nominee, and no vote on such Shareholder Nominee will occur, notwithstanding that proxies in respect of such vote may have been received by the Corporation:

 

(i)                  who is not independent under the listing standards of the NYSE, any applicable rules of the Securities and Exchange Commission and any publicly disclosed standards used by the Board of Directors in determining and disclosing independence of the Corporation’s directors, in each case as determined by the Board of Directors, who does not meet the audit committee independence requirements under the rules of any stock exchange on which the Corporation’s securities are traded and applicable securities laws, who is not a “non-employee director” for the purposes of Rule 16b-3 under the Exchange Act (or any successor rule), or who is not independent for the purposes of the requirements under the FDIC Improvement Act related to designation as an “outside director”;

 

(ii)                whose service as a member of the Board of Directors would violate or cause the Corporation to be in violation of these Bylaws, the Corporation’s Articles of Incorporation, the rules and listing standards of the NYSE, or any applicable law, rule or regulation;

 

11 

 

 

(iii)              who is or has been, within the past three years, an officer or director of a competitor, as defined in Section 8 of the Clayton Antitrust Act of 1914;

 

(iv)               whose then-current or within the preceding ten (10) years’ business or personal interests place such Shareholder Nominee in a conflict of interest with the Corporation or any of its subsidiaries that would cause such Shareholder Nominee to violate any fiduciary duties of directors established pursuant to Indiana law, as determined by the Board of Directors;

 

(v)                who is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses) or has been convicted in such a criminal proceeding within the past ten (10) years;

 

(vi)               who is subject to any order of the type specified in Rule 506(d) of Regulation D promulgated under the Securities Act;

 

(vii)             if the Eligible Shareholder (or any Constituent Holder) or applicable Shareholder Nominee otherwise breaches or fails to comply in any material respect with its obligations pursuant to this Section 1.11 or any agreement, representation or undertaking required by this Section 1.11;

 

(viii)           if the Eligible Shareholder ceases to be an Eligible Shareholder for any reason, including but not limited to not owning the Proxy Access Request Required Shares through the date of the applicable annual meeting; or

 

(ix)               if the Corporation receives a notice pursuant to Section 1.10 of these Bylaws that a shareholder intends to nominate a candidate for director at the annual meeting of shareholders;

 

For the purposes of this paragraph, clauses (i) and (ii) and, to the extent related to a breach or failure by the Shareholder Nominee, clause (iii) will result in the exclusion from the proxy materials pursuant to this Section 1.11 of the specific Shareholder Nominee to whom the ineligibility applies, or, if the proxy statement already has been filed, the ineligibility of such Shareholder Nominee to be nominated; provided, however, that clause (iv) and, to the extent related to a breach or failure by an Eligible Shareholder (or any Constituent Holder), clause (iii) will result in the Voting Stock owned by such Eligible Shareholder (or Constituent Holder) being excluded from the Proxy Access Request Required Shares (and, if as a result the Proxy Access Notice shall no longer have been filed by an Eligible Shareholder, the exclusion from the proxy materials pursuant to this Section 1.11 of all of the applicable shareholder’s Shareholder Nominees from the applicable annual meeting of shareholders or, if the proxy statement has already been filed, the ineligibility of all of such shareholder’s Shareholder Nominees to be nominated).

 

Article II

Board of Directors

 

Section 2.1.          General Powers. The property, affairs and business of the Corporation shall be managed under the direction of the Board of Directors. In addition to the powers and authorities by these Bylaws expressly conferred upon them, the Board of Directors may exercise all such powers of the Corporation and do all such lawful acts and things as are not by statute or by the Articles of Incorporation or by these Bylaws required to be exercised or done by the shareholders.

 

Section 2.2.          Number and Qualifications. The number of directors which shall constitute the Board of Directors shall be nine (9), which number may be either increased or diminished by resolution adopted by not less than a majority of the directors then in office; provided that the number may not be diminished below five (5), and no reduction in number shall have the effect of shortening the term of any incumbent director. In the event that the holders of shares of preferred stock become entitled to elect a certain number of directors, the number of directors and the minimum number of directors shall be increased by such number. Neither ownership of stock of the Corporation nor residence in the State of Indiana shall be required as a qualification for a director.

 

12 

 

 

Section 2.3.          Classes of Directors and Terms. The classes of directors and terms shall be divided into three classes as nearly equal in number as possible. Except as provided in Article 9 of the Articles of Incorporation fixing one, two and three year terms for the initial classified board, each class of directors shall be elected for a term of three (3) years. In the event of vacancy, either by death, resignation, or removal of a director, or by reason of an increase in the number of directors, each replacement or new director shall serve for the balance of the term of the class of the director he or she succeeds or, in the event of an increase in the number of directors, of the class to which he or she is assigned. All directors elected for a term shall continue in office until the election and qualification of their respective successors, their death, their resignation in accordance with Section 2.7, their removal in accordance with Section 2.8, or if there has been a reduction in the number of directors until the end of their respective terms. The classes and terms of the directors shall not be governed by IND. CODE §23-1- 33-6(c).

 

Section 2.4.          Election of Directors. Subject to the rights of the holders of preferred stock to elect any directors voting separately as a class or series, at each meeting of shareholders, the directors to be elected at the meeting shall be chosen by the plurality of the votes cast by the holders of shares entitled to vote in the election at the meeting, provided a quorum is present. For purposes of this Section 2.4, a “plurality of the votes cast” shall mean that the individuals with the highest number of votes are elected as directors up to the maximum number of directors to be elected.

 

The election of directors by the shareholders shall be by written ballot if directed by the chairman of the meeting or if the number of nominees exceeds the number of directors to be elected.

 

Any vacancy on the Board of Directors shall be filled by the affirmative vote of a majority of the remaining directors.

 

If the holders of preferred stock are entitled to elect any directors voting separately as a class or series, those directors shall be elected by a plurality of the votes cast by the holders of shares of preferred stock entitled to vote in the election at the meeting, provided a quorum of the holders of shares of preferred stock is present.

 

Section 2.5.          Meetings of Directors.

 

(a)                 Annual Meeting. Unless otherwise provided by resolution of the Board of Directors, the annual meeting of the Board of Directors shall be held at the place of and immediately following the annual meeting of shareholders, for the purpose of organization, the election of officers and the transaction of such other business as properly may come before the meeting. No notice of the meeting need be given, except in the case an amendment to the Bylaws is to be considered.

 

(b)                Regular Meetings. The Board of Directors by resolution may provide for the holding of regular meetings and may fix the times and places (within or outside the State of Indiana) at which those meetings shall be held. Notice of regular meetings need not be given except when an amendment to the Bylaws is to be considered. Whenever the time or place of regular meetings shall be fixed or changed, notice of this action shall be mailed promptly to each director not present when the action was taken, addressed to the director at his or her residence or usual place of business.

 

(c)                 Special Meetings. Special meetings of the Board of Directors may be called by the Chairman of the Board and shall be called by the Secretary at the request of a majority of the directors then in office. Except as otherwise required by statute, notice of each special meeting shall be mailed to each director at his or her residence or usual place of business at least three (3) days before the day on which the meeting is to be held, or shall be sent to the director at such place by facsimile transmission or other form of electronic communication or personally delivered, not later than twelve (12) hours in advance of when the meeting is to be held. The notice shall state the time and place (which may be within or outside the State of Indiana) of the meeting but, unless otherwise required by statute, the Articles of Incorporation or the Bylaws, need not state the purposes thereof.

 

Notice of any meeting need not be given to any director, however, who shall attend the meeting, or who shall waive notice thereof, before, at the time of, or after the meeting, in a writing signed by the director and delivered to the Corporation. No notice need be given of any meeting at which every member of the Board of Directors shall be present.

 

13 

 

 

Section 2.6.          Quorum and Manner of Acting. A majority of the actual number of directors established pursuant to Section 2.2, from time to time, shall be necessary to constitute a quorum for the transaction of any business except the filling of vacancies on the Board of Directors under Section 2.4 or voting on a conflict of interest transaction under Section 2.12. The act of a majority of the directors present at a meeting at which a quorum is present, shall be the act of the Board of Directors, unless the act of a greater number is required by statute, by the Articles of Incorporation, or by the Bylaws. Any or all directors may participate in a meeting of the Board of Directors or any committee thereof by means of a conference telephone or similar communications equipment by which all persons participating in the meeting may simultaneously hear each other, and participation in this manner shall constitute presence in person at the meeting. In the absence of a quorum, a majority of the directors present may adjourn the meeting from time to time until a quorum shall be present. No notice of any adjourned meeting need be given.

 

Section 2.7.          Resignations. Any director may resign at any time by giving written notice of resignation to the Board of Directors, the Chairman of the Board, the Chief Executive Officer, or the Secretary. Unless otherwise specified in the written notice, the resignation shall take effect upon receipt thereof and unless otherwise specified in it, the acceptance of the resignation shall not be necessary to make it effective.

 

Section 2.8.          Removal of Directors. Any director, other than a director elected by holders of preferred stock voting as a class, may be removed from office at any time but only for cause and only upon the affirmative vote of at least sixty-six and two-thirds percent (66 2/3%) of the votes entitled to be cash by holders of all of the outstanding shares of Voting Stock (as defined in Article 9(e) of the Articles of Incorporation), voting together as a single class.

 

Section 2.9.          Action without a Meeting. Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if taken by all members of the Board of Directors or such committee, as the case may be, evidenced by a written consent signed by all such members and effective on the date, either prior or subsequent to the date of the consent, specified in the written consent, or if no effective date is specified in the written consent, the date on which the consent is filed with the minutes of proceedings of the Board of Directors or committee.

 

Section 2.10.      Chairman of the Board of Directors. The Chairman of the Board shall preside at all meetings of the shareholders and of the Board of Directors, if present, and shall have such powers and perform such duties as are assigned to him or her by the Bylaws and by the Board of Directors. At any time in which the Chairman of the Board is unable to discharge the powers and duties of the office, then until such time as the Board shall appoint a new Chairman or determines that the Chairman is able to resume office, temporary authority to perform such duties and exercise such powers shall be granted to the Chief Executive Officer, or if he or she is unable to perform such duties and exercise such powers, to the Board’s presiding or lead director (if one shall have been previously selected).

 

Section 2.11.      Committees. The Board of Directors may designate from among its members one or more committees. Such committees shall have those powers of the Board of Directors which may by law be delegated to such committees and are specified by resolution of the Board of Directors or by committee charters approved by the Board of Directors.

 

Section 2.12.      Transactions with Corporation. No transactions with the Corporation in which one or more of its directors has a direct or indirect interest shall be either void or voidable solely because of such interest if any one of the following is true:

 

(a)                 the material facts of the transaction and the director’s interest are disclosed or known to the Board of Directors or committee which authorizes, approves, or ratifies the transaction by the affirmative vote or consent of a majority of the directors (or committee members) who have no direct or indirect interest in the transaction and, in any event, of at least two directors (or committee members);

 

(b)                the material facts of the transaction and the director’s interest are disclosed or known to the shareholders entitled to vote and they authorize, approve or ratify such transaction by vote; or

 

(c)                 the transaction is fair to the Corporation.

 

14 

 

 

If a majority of the directors or committee members who have no direct or indirect interest in the transaction vote to authorize, approve, or ratify the transaction, a quorum is present for purposes of taking action under subsection (a) of this section. The presence of, or a vote cast by, a director with a direct or indirect interest in the transaction does not affect the validity of any actions taken under subsection (a) of this section.

 

Section 2.13.      Compensation of Directors. The Board of Directors is empowered and authorized to fix and determine the compensation of directors and additional compensation for such additional services any of such directors may perform for the Corporation.

 

Article III

Officers

 

Section 3.1.          Chief Executive Officer. The Board of Directors shall appoint a Chief Executive Officer to serve at the pleasure of the Board of Directors. The Chief Executive Officer shall have general supervisory responsibility over the business of the Corporation and shall see that all orders and resolutions of the Board of Directors are carried into effect. He or she shall be the primary executive officer of the Corporation and shall execute all bonds, mortgages, contracts and other instruments of the Corporation requiring a seal, under the seal of the Corporation, except where required or permitted by law to be otherwise signed and executed and except that the other officers of the Corporation may sign and execute documents when so authorized by these Bylaws, the Board of Directors or the Chief Executive Officer. In the absence or disability of the Chairman of the Board, the Chief Executive Officer shall preside at all meetings of the stockholders and the Board of Directors. The Chief Executive Officer shall also perform such other duties and may exercise such other powers as from time to time may be assigned to him or her by these Bylaws or by the Board of Directors.

 

Section 3.2.          Chief Financial Officer. The Board of Directors shall appoint a Chief Financial Officer of the Corporation to serve at the pleasure of the Board of Directors. The Chief Financial Officer shall, subject to the control of the Board of Directors, have the responsibility for maintaining the financial records of the Corporation. He or she shall render from time to time an account of the financial condition of the Corporation. The Chief Financial Officer shall also perform such other duties and may exercise such other powers as from time to time may be assigned to him or her by these Bylaws.

 

Section 3.3.          Secretary and Assistant Secretaries. The Board of Directors shall appoint a Secretary of the Corporation to serve at the pleasure of the Board of Directors. The Secretary of the Corporation shall (a) keep minutes of all meetings of the shareholders and of the Board of Directors, (b) authenticate records of the Corporation, (c) give, or cause to be given, notice of all meetings of the shareholders and special meetings of the Board of Directors, and (d) in general, have such powers and perform such other duties as may be assigned to him or her by these Bylaws, as may from time to time be assigned to him or her by the Board of Directors or the Chief Executive Officer and as may be incident to the office of Secretary of the Corporation. If the Secretary shall be unable or shall refuse to cause to be given notice of all meetings of the shareholders and special meetings of the Board of Directors, and if there be no Assistant Secretary, then the Board of Directors may choose another officer to cause such notice to be given. The Secretary shall have custody of the seal of the Corporation and the Secretary or any Assistant Secretary, if there be one, shall have authority to affix the same to any instrument requiring it and when so affixed, it may be attested by the signature of the Secretary or by the signature of any such Assistant Secretary. The Board of Directors may give general authority to any other officer to affix the seal of the Corporation and to attest to the affixing by such officer’s signature. The Secretary shall see that all books, reports, statements certificates and other documents and records required by law to be kept or filed are properly kept or filed, as the case may be.

 

Section 3.4.          Treasurer. The Treasurer, if any, shall perform such duties and shall have such powers as may from time to time be assigned by the Board of Directors or the Chief Executive Officer. In addition, the Treasurer shall perform such duties and have such powers as are incident to the office of treasurer, including without limitation the duty and power to keep and be responsible for all funds and securities of the Corporation, to deposit funds of the Corporation in depositories selected in accordance with these Bylaws, to disburse such funds as authorized by the Board of Directors or the Chief Executive Officer, to make proper accounts of such funds, and to render as required by the Board of Directors statements of all such transactions and of the financial condition of the Corporation.

 

15 

 

 

Section 3.5.          Other Officers. At any meeting of the Board of Directors, the Board of Directors may elect a President (who may or may not be the Chief Executive Officer), Vice Presidents (who may be designated as Executive Vice Presidents, Senior Vice Presidents or have other similar titles), Assistant Treasurers, Assistant Secretaries or such other officers of the Corporation as the Board of Directors may deem necessary, to serve at the pleasure of the Board of Directors. Other officers elected by the Board of Directors shall have such powers and perform such duties as may be assigned to such officers by or pursuant to authorization of the Board of Directors or by the Chief Executive Officer. Any two (2) or more offices may be held by the same person. The Board of Directors may delegate to any officer the power to appoint any such officers or agents and to prescribe their respective terms of office, powers and duties.

 

Section 3.6.          Term of Office. Each officer shall hold office until his or her successor shall have been duly elected and shall have qualified or until his or her death or until he or she shall resign, but, subject to the requirements of the Articles of Incorporation, any officer may be removed in the manner provided in Section 3.8 of these Bylaws.

 

Section 3.7.          Resignation. Any officer may resign at any time by giving written notice of such resignation to the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the Secretary of the Corporation. Unless otherwise specified in such written notice, such resignation shall take effect upon receipt thereof and unless otherwise specified in it, the acceptance of the resignation shall not be necessary to make it effective.

 

Section 3.8.          Removal. Officers of the Corporation may be removed or suspended, either for or without cause, at any meeting of the Board of Directors called for the purpose, by the vote of a majority of the actual number of directors elected and qualified. The officers and agents elected or appointed in accordance with the provisions of Sections 3.1-3.5 may be removed or suspended, either for or without cause, at any meeting of the Board of Directors at which a quorum be present, by the vote of a majority of the directors present at such meeting, by any officer upon whom such power of removal or suspension shall have been conferred by the Board of Directors, or by any officer to whom the power to appoint such officer has been delegated by the Board of Directors pursuant to Section 3.5. Any removal or suspension shall be without prejudice to the contract rights, if any, of the person so removed or suspended.

 

Section 3.9.          Vacancies. A vacancy in any office by reason of death, resignation, removal, disqualification or any other cause, may be filled by the Board of Directors or by an officer authorized under these Bylaws to appoint a person to serve in such office.

 

Article IV

Execution of Instruments and Deposit of Corporate Funds

 

Section 4.1.          Execution of Instruments Generally. All deeds, contracts, and other instruments requiring execution by the Corporation may be signed by the Chairman of the Board, the Chief Executive Officer, the Chief Financial Officer, the Treasurer, the Secretary or any Assistant Treasurer or Assistant Secretary of the Corporation. Authority to sign any deed, contract, or other instrument requiring execution by the Corporation may be conferred by the Board of Directors upon any person or persons whether or not such person or persons be officers of the Corporation. Such person or persons may delegate, from time to time, by instrument in writing, all or any part of such authority to any other person or persons if authorized so to do by the Board of Directors.

 

Section 4.2.          Notes, Checks, Other Instruments. All notes, drafts, acceptances, checks, endorsements, and all evidences of indebtedness of the Corporation whatsoever, shall be signed by such officer or officers or such agent or agents of the Corporation and in such manner as the Board of Directors from time to time may determine. Endorsements for deposit to the credit of the Corporation in any of its duly authorized depositories shall be made in such manner as the Board of Directors from time to time may determine.

 

16 

 

 

Section 4.3.          Proxies. Proxies, powers of attorney, or consents to vote with respect to shares or units of other corporations or other entities owned by or standing in the name of the Corporation may be executed and delivered from time to time on behalf of the Corporation by the Chairman of the Board, the Chief Executive Officer, the Chief Financial Officer, the President, any Vice President, the Treasurer, any Assistant Treasurer, the Secretary or by any other person or persons thereunto authorized by the Board of Directors. Persons with authority to execute proxies, powers of attorney, or consents under this Section 4.3 may delegate that authority unless prohibited by the Board of Directors.

 

Article V

Shares

 

Section 5.1.          Certificates for Shares. Shares in the Corporation may be issued in book-entry form or evidenced by certificates. However, every holder of shares in the Corporation shall be entitled upon request to have a certificate evidencing the shares owned by the shareholder, signed in the name of the Corporation by the Chairman of the Board, the Chief Executive Officer, President or a Vice President and the Secretary or an Assistant Secretary, certifying the number of shares owned by the shareholder in the Corporation. The signatures of such officers, the signature of the transfer agent and registrar, and the Seal of the Corporation may be facsimiles. In case any officer or employee who shall have signed, or whose facsimile signature or signatures shall have been used on, any certificate shall cease to be an officer or employee of the Corporation before the certificate shall have been issued and delivered by the Corporation, the certificate may nevertheless be adopted by the Corporation and be issued and delivered as though the person or persons who signed the certificate or whose facsimile signature or signatures shall have been used thereon had not ceased to be such officer or employee of the Corporation; and the issuance and delivery by the Corporation of any such certificate shall constitute an adoption thereof. Every certificate shall state on its face (or in the case of book-entry shares, the statements evidencing ownership of such shares shall state) the name of the Corporation and that it is organized under the laws of the State of Indiana, the name of the person to whom it is issued, and the number and class of shares and the designation of the series, if any, the certificate represents, and shall state conspicuously on its front or back that the Corporation will furnish the shareholder, upon written request and without charge, a summary of the designations, relative rights, preferences and limitations applicable to each class and the variations in rights, preferences and limitations determined for each series (and the authority of the Board of Directors to determine variations for future series). Every certificate (or book-entry statement) shall state whether such shares have been fully paid and are non-assessable. If any such shares are not fully paid, the certificate (or book-entry statement) shall be legibly stamped to indicate the percentum which has been paid up, and as further payments are made thereon, the certificate shall be stamped (or book- entry statement updated) accordingly. Subject to the foregoing provisions, certificates representing shares in the Corporation shall be in such form as shall be approved by the Board of Directors. There shall be entered upon the stock books of the Corporation at the time of the issuance or transfer of each share the number of the certificates representing such share (if any), the name of the person owning the shares represented thereby, the class of such share and the date of the issuance or transfer thereof.

 

Section 5.2.          Transfer of Shares. Transfer of shares of the Corporation shall be made on the books of the Corporation by the holder of record thereof, or by the shareholder’s attorney thereunto duly authorized in writing and filed with the Secretary of the Corporation or any of its transfer agents, and on surrender of the certificate or certificates (if any) representing such shares. The Corporation and its transfer agents and registrars shall be entitled to treat the holder of record of any share or shares the absolute owner thereof for all purposes, and accordingly shall not be bound to recognize any legal, equitable or other claim to or interest in such share or shares on the part of any other person whether or not it or they shall have express or other notice thereof, except as otherwise expressly provided by the statutes of the State of Indiana. Shareholders shall notify the Corporation in writing of any changes in their addresses from time to time.

 

Section 5.3.          Regulations. Subject to the provisions of this Article V, the Board of Directors may make such rules and regulations as it may deem expedient concerning the issuance, transfer and regulation of certificates for shares or book-entry shares of the Corporation.

 

17 

 

 

Section 5.4.          Transfer Agents and Registrars. The Board of Directors may appoint one or more transfer agents, one or more registrars, and one or more agents to act in the dual capacity of transfer agent and registrar with respect to the certificates representing shares and the book-entry shares of the Corporation.

 

Section 5.5.          Lost or Destroyed Certificates. The holders of any shares of the Corporation shall immediately notify the Corporation or one of its transfer agents and registrars of any loss or destruction of the certificate representing the same. The Corporation may issue a new certificate in the place of any certificate theretofore issued by it alleged to have been lost or destroyed upon such terms and under such regulations as may be adopted by the Board of Directors or the Secretary, and the Board of Directors or Secretary may require the owner of the lost or destroyed certificate or the owner’s legal representatives to give the Corporation a bond in such form and for such amount as the Board of Directors or Secretary may direct, and with such surety or sureties as may be satisfactory to the Board of Directors or the Secretary to indemnify the Corporation and its transfer agents and registrars against any claim that may be made against it or any such transfer agent or registrar on account of the alleged loss or destruction of any such certificate or the issuance of such new certificate. A new certificate may be issued without requiring any bond when, in the judgment of the Board of Directors or the Secretary, it is proper so to do.

 

Article VI

Indemnification

 

Section 6.1.          Right to Indemnification.

 

(a)                 The Corporation shall, to the fullest extent permitted by applicable law now or hereafter in effect, indemnify any person who is or was a director, officer or employee of the Corporation (“Eligible Person”) and who is or was involved in any manner (including, without limitation, as a party or a witness) or is threatened to be made so involved in any threatened, pending or completed investigation, claim, action, suit or proceeding, whether civil, criminal, administrative or investigative (including, without limitation, any action, suit or proceeding by or in the right of the Corporation to procure a judgment in its favor) (a “Proceeding”) by reason of the fact that such Eligible Person is or was a director, officer or employee of the Corporation or is or was serving at the request of the Corporation as a director, officer, partner, member, manager, trustee, employee, fiduciary or agent of another corporation, partnership, joint venture, limited liability company, trust or other enterprise (including, without limitation, any employee benefit plan) (a “Covered Entity”), against all expenses (including attorneys’ fees), judgments, fines or penalties (including excise taxes assessed with respect to an employee benefit plan) and amounts paid in settlement actually and reasonably incurred by such Eligible Person in connection with such Proceeding.

 

(b)                Notwithstanding Section 6.1(a), the Corporation shall not be obligated to indemnify an Eligible Person with respect to a Proceeding (or part thereof) commenced by such Eligible Person, except with respect to (i) a judicial adjudication or arbitration commenced by the Eligible Person under Section 6.5(e) or (f), as to which the rights to indemnification are provided pursuant Section 6.5(h), or (ii) a Proceeding (or part thereof) that was authorized or consented to by the Board of Directors of the Corporation.

 

(c)                 In the event a Proceeding arises out of an Eligible Person’s service to a Covered Entity, the indemnification provided by the Corporation under this Article VI shall be secondary to and not pari passu with any indemnification provided by the Covered Entity. However, the Corporation may provide indemnification to the Eligible Person in the first instance, in which case the Corporation shall be subrogated to the extent of such payment to the rights of the Eligible Person with respect to the indemnification provided by the Covered Entity and any insurance coverage maintained by the Covered Entity on behalf of the Eligible Person.

 

(d)                Any right of an Eligible Person to indemnification shall be a contract right and shall include the right to receive, prior to the conclusion of any Proceeding, advancement of any expenses incurred by the Eligible Person in connection with such Proceeding in accordance with Section 6.4.

 

Section 6.2.          Insurance, Contracts and Funding. The Corporation may purchase and maintain insurance to protect itself and any Eligible Person against any expense, judgments, fines and amounts paid in settlement as specified in Section 6.1 or incurred by any Eligible Person in connection with any Proceeding referred to in such section, to the fullest extent permitted by applicable law now or hereafter in effect. The Corporation may enter into agreements with any director, officer, employee or agent of the Corporation or any director, officer, employee, fiduciary or agent of any Covered Entity supplemental to or in furtherance of the provisions of this Article VI and may create a trust fund or use other means (including, without limitation, a letter of credit) to ensure the payment of such amounts as may be necessary to effect indemnification and advancement of expenses as provided in this Article VI.

 

18 

 

 

Section 6.3.          Non-Exclusive Rights; Applicability to Certain Proceedings. The rights provided in this Article VI shall not be exclusive of any other rights to which any Eligible Person may otherwise be entitled, and the provisions of this Article VI shall inure to the benefit of the heirs and legal representatives of any Eligible Person and shall be applicable to Proceedings commenced or continuing after the adoption of this Article VI, whether arising from acts or omissions occurring before or after such adoption.

 

Section 6.4.          Advancement of Expenses.

 

(a)                 Except as provided under Sections 6.4(b) and (c) below, all reasonable expenses incurred by or on behalf of an Eligible Person in connection with any Proceeding shall be advanced to the Eligible Person by the Corporation within sixty (60) days after the receipt by the Corporation of a statement or statements from the Eligible Person complying with this section and Section 6.5 requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding, unless a determination has been made pursuant to Section 6.5 that such Eligible Person is not entitled to indemnification. Any such statement or statements shall reasonably evidence the expenses incurred by the Eligible Person and shall include (i) a written representation that, in connection with the matters giving rise to the Proceeding, the Eligible Person was acting in good faith and in what he or she believed to be the best interests of the Corporation or at least not opposed to the best interests of the Corporation, and (ii) a written affirmation or undertaking to repay advances if it is ultimately determined that the Eligible Person is not entitled to indemnification under this Article VI.

 

(b)                Notwithstanding Section 6.4(a), advancement of expenses shall not be mandatory, but shall be permissive at the discretion of the Corporation, for expenses incurred after the Eligible Person’s conviction by a trial court of competent jurisdiction of, or plea of guilty or nolo contendere or its equivalent to, a crime arising from the circumstances giving rise to the Proceeding.

 

(c)                 Notwithstanding Section 6.4(a), advancement of expenses shall not be mandatory, but shall be permissive at the discretion of the Corporation, for expenses incurred by or on behalf of Eligible Persons for judicial adjudications or arbitrations under Section 6.5(e) or (f).

 

Section 6.5.          Procedures; Presumptions and Effect of Certain Proceedings; Remedies. In furtherance, but not in limitation, of the foregoing provisions, the following procedures, presumptions and remedies shall apply with respect to and the right to indemnification and advancement of expenses under this Article VI.

 

(a)                 To obtain indemnification under this Article VI, an Eligible Person shall submit to the Secretary of the Corporation a written request, including such documentation and information as is reasonably available to the Eligible Person and reasonably necessary to determine whether and to what extent the Eligible Person is entitled to indemnification (the “Supporting Documentation”). The determination of the Eligible Person’s entitlement to indemnification shall be made not later than sixty (60) days after receipt by the Corporation of the written request together with the Supporting Documentation. The Secretary of the Corporation shall, promptly upon receipt of such request, advise the Board in writing of the Eligible Person’s request.

 

(b)                An Eligible Person’s entitlement to indemnification under this Article VI shall be determined in one of the following methods, such method to be selected by the Board of Directors, regardless of whether there are any Disinterested Directors (as hereinafter defined): (i) by a majority vote of the Disinterested Directors, if they constitute a quorum of the Board; (ii) if a quorum of the Board consisting of Disinterested Directors is not obtainable, by a committee designated by the Board consisting of two (2) or more Disinterested Directors, (iii) by a written opinion of Special Counsel (as hereinafter defined) if a quorum of the Board consisting of Disinterested Directors is not obtainable or, even if obtainable, a majority of such Disinterested Directors so directs; (iii) by the shareholders of the Corporation (but only if a majority of the Disinterested Directors, if they constitute a quorum of the Board, presents the issue of entitlement to the shareholders for their determination); or (iv) as provided in subsection (d).

 

19 

 

 

(c)                 In the event the determination of entitlement is to be made by Special Counsel, a majority of the Disinterested Directors shall select the Special Counsel, but only Special Counsel to which the Eligible Person does not reasonably object.

 

(d)                In any event, if the person or persons empowered under subsection (b) to determine entitlement shall not have been appointed or shall not have made a determination within sixty (60) days (120 days in the case of a determination to be made by shareholders) after receipt by the Corporation of the request therefor together with the Supporting Documentation, the Eligible Person shall be deemed to be, and shall be, entitled to indemnification and advancement of expenses unless (i) the Eligible Person misrepresented or failed to disclose a material fact in making the request for indemnification or in the Supporting Documentation or (ii) such indemnification is prohibited by law. The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, adversely affect the right of an Eligible Person to indemnification or create a presumption that the Eligible Person did not act in good faith and in a manner which the Eligible Person reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, that the Eligible Person had reasonable cause to believe that his or her conduct was unlawful.

 

(e)                 In the event that a determination is made that the Eligible Person is not entitled to indemnification (i) the Eligible Person shall be entitled to seek an adjudication of his or her entitlement to such indemnification either, at the Eligible Person’s sole option, in (A) an appropriate court of the State of Indiana or any other court of competent jurisdiction or (B) an arbitration to be conducted in Indianapolis, Indiana, by a single arbitrator pursuant to the rules of the American Arbitration Association; and (ii) in any such judicial proceeding or arbitration the Eligible Person shall not be prejudiced by reason of the prior determination pursuant to this Section 6.5.

 

(f)                  If a determination shall have been made or deemed to have been made that the Eligible Person is entitled to indemnification, the Corporation shall be obligated to pay the amounts incurred by the Eligible Person within ten (10) days after such determination has been made or deemed to have been made and shall be conclusively bound by such determination unless (i) the Eligible Person misrepresented or failed to disclose a material fact in making the request for indemnification or in the Supporting Documentation or (ii) such indemnification is prohibited by law. In the event that (A) any advancement of expenses is not timely made pursuant to Section 6.4 or (B) payment of indemnification is not made within ten (10) days after a determination of entitlement to indemnification has been made, the Eligible Person shall be entitled to seek judicial enforcement of the Corporation’s obligation, to pay to the Eligible Person such advancement of expenses or indemnification. Notwithstanding the foregoing, the Corporation may bring an action, in an appropriate court in the State of Indiana or any other court of competent jurisdiction, contesting the right of the Eligible Person to receive indemnification hereunder due to the occurrence of an event described in clause (i) or (ii) of this subsection (f) (a “Disqualifying Event”); provided, however, that in any such action the Corporation shall have the burden of proving the occurrence of such Disqualifying Event.

 

(g)                The Corporation shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 6.5 that the procedures and presumptions of this Article VI are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Corporation is bound by the provisions of this Article VI.

 

(h)                In the event that the Eligible Person seeks a judicial adjudication of or an award in arbitration to enforce his or her rights under, or to recover damages for breach of this Article VI, the Eligible Person shall be entitled to recover from the Corporation, and shall be indemnified by the Corporation, against, any expenses actually and reasonably incurred by the Eligible Person in connection with such adjudication or arbitration if the Eligible Person prevails in such adjudication or arbitration. If it shall be determined in such judicial adjudication or arbitration that the Eligible Person is entitled to receive part but not all of the indemnification or advancement of expenses sought, the expenses incurred by the Eligible Person in connection with such judicial adjudication or arbitration shall be prorated accordingly.

 

20 

 

 

Section 6.6.          Certain Definitions. For purposes of this Article VI:

 

(a)                 “Disinterested Director” means a Director who is not or was not a party to the Proceeding in respect of which indemnification is sought by the Eligible Person.

 

(b)                “Special Counsel” means a law firm or a member of a law firm that neither presently is, nor in the past five years has been, retained to represent any other party to the Proceeding giving rise to a claim for indemnification under this Article VI. In addition, any person who, under applicable standards of professional conduct, would have a conflict of interest in representing either the Corporation or the Eligible Person in an action to determine the Eligible Person’s rights under this Article VI may not act as Special Counsel.

 

Section 6.7.          Indemnification of Agents. Notwithstanding any other provisions of this Article VI, the Corporation may, consistent with the provisions of applicable law, indemnify any person other than a director, officer or employee of the Corporation who is or was an agent of the Corporation and who is or was involved in any manner (including, without limitation, as party or a witness) or is threatened to be made so involved in any threatened, pending or completed Proceeding by reasons of the fact that such person is or was an agent of the Corporation or, at the request of the Corporation, a director, officer, partner, member, manager, employee, fiduciary or agent of a Covered Entity against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such Proceeding. The Corporation may also advance expenses incurred by such person in connection with any such Proceeding, consistent with the provisions of applicable law.

 

Section 6.8.          Effect of Amendment or Repeal. Neither the amendment or repeal of, nor the adoption of a provision inconsistent with, any provision of this Article VI shall adversely affect the rights of any Eligible Person under this Article VI with respect to any Proceeding commenced or threatened prior to such amendment, repeal or adoption of an inconsistent provision without the written consent of such Eligible Person.

 

Section 6.9.          Severability. If any of this Article VI shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Article VI (including, without limitation, all portions of any Section of this Article VI containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Article VI (including, without limitation, all portions of any Section of this Article VI containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

Article VII

Miscellaneous

 

Section 7.1.          Corporate Seal. The Seal of the Corporation shall consist of a circular disk around the circumference of which shall appear the words:

 

“ELANCO ANIMAL HEALTH INCORPORATED, GREENFIELD, INDIANA”.

 

Section 7.2.          Fiscal Year. The fiscal year of the Corporation shall begin on the first day of January in each year and shall end on the thirty-first day of the following December.

 

Section 7.3.          Exclusive Forum. Unless the Corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, a state court located within Hancock County, Indiana or Marion County, Indiana or, if no such state court has jurisdiction, the federal district court for the Southern District of Indiana, shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director or officer or other employee or shareholder of the Corporation (iii) any action asserting a claim against the Corporation or any director or officer or other employee of the corporation arising pursuant to any provision of the Indiana Business Corporation Law, as amended from time to time, or the Articles of Incorporation or these Bylaws (as either may be amended from time to time), (iv) any action to interpret, apply, enforce or determine the validity of the Articles of Incorporation or these Bylaws or (v) any action asserting a claim governed by the internal affairs doctrine.

 

* * *

 

21 

 

EX-99.1 3 tm227491d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

FOR IMMEDIATE RELEASE

 

Investor Contact: Kathryn Grissom (317) 273-9284 or kathryn.grissom@elancoah.com

 

Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com

 

Elanco Animal Health Reports Fourth Quarter and Full Year 2021 Results

 

Full year 2021 revenue was $4,765 million, an increase of 46 percent, including $1,311 million of incremental revenue from Bayer Animal Health products in 2021. Full year 2021 earnings per share (EPS) was $(0.97) (reported), or $1.05 (adjusted).

 

Fourth quarter 2021 revenue was $1,113 million, a decline of 2 percent. Excluding the unfavorable impact of $60 million of previously disclosed items that benefited the fourth quarter of 2020 and the unfavorable impact of foreign exchange rates, fourth quarter 2021 revenue increased 4 percent. Fourth quarter 2021 EPS was $(0.20) (reported), or $0.21 (adjusted), an increase of 70 percent as reported and 75 percent on an adjusted basis.

 

Providing financial guidance for the full year 2022 with revenue of $4,745 to $4,800 million, representing growth on a reported basis at the midpoint and 2 to 3 percent growth on a constant currency basis, and diluted EPS of $0.01 to $0.07 on a reported basis, or $1.18 to $1.24 on an adjusted basis.

 

Significant innovation progress in 2022: Innovation revenue expected to contribute $120 to $160 million; expect 7 approvals and launches and 5 to 7 regulatory submissions in major markets, including up to two differentiated pet health potential blockbusters.

 

Providing financial guidance for the first quarter 2022 with revenue of $1,200 to $1,230 million, and diluted EPS of $0.01 to $0.07 on a reported basis, or $0.33 to $0.38 on an adjusted basis.

 

GREENFIELD, IN (February 24, 2022) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2021, and provided initial guidance both for the first quarter and full year 2022.

 

“2021 was a historic year for Elanco as we completed our independent company standup, continued our integration of Bayer Animal Health and recorded our highest revenue and adjusted EBITDA levels as a public company. We grew revenue 7 percent compared to our 2020 pro forma combined company estimates, including 10 percent in Pet Health and 6 percent in Farm Animal,” said Jeff Simmons, president and CEO of Elanco. “The fourth quarter of 2021 represents our 5th consecutive quarter of outperforming our expectations. Our diverse portfolio delivered across the business – growing in all three regions and in four out of five species, demonstrating the durable growth profile of our business. None of this would be possible without the dedicated customers we serve and the commitment and ownership mindset of our global Elanco team. The resiliency they demonstrated and their disciplined focus on execution was central to where we are today. We carry this momentum into 2022, anticipating 2 to 3 percent revenue growth on a constant currency basis and 10 percent adjusted EBITDA and 15 percent adjusted EPS growth at the midpoint of our guidance, with seven new product approvals and launches and 5 to 7 new product submissions expected.”

 

1

 

 

Fourth Quarter Results

(dollars in millions, except per share amounts)

  2021   2020   Change ($)   Change (%) 
Revenue  $1,113   $1,140   $(27)   (2)%
Reported Net Loss  $(97)  $(323)  $226    70%
Adjusted EBITDA  $212   $176   $36    20%
Reported EPS  $(0.20)  $(0.66)  $0.46    70%
Adjusted EPS  $0.21   $0.12   $0.09    75%

 

Full Year Results

(dollars in millions, except per share amounts)

  2021   2020   Change ($)   Change (%) 
Revenue  $4,765   $3,273   $1,492    46%
Reported Net Loss  $(472)  $(560)  $88    16%
Adjusted EBITDA  $1,057   $529   $528    100%
Reported EPS  $(0.97)  $(1.27)  $0.30    24%
Adjusted EPS  $1.05   $0.47   $0.58    123%

 

Highlights Since Last Earnings Call:

 

Innovation

 

Innovation-related revenue in 2021 was $72 million, within the most recent guidance range of $65 million to $85 million, driven by Credelio Plus and Increxxa.

 

Received FDA approval for ZorbiumTM, a long-acting transdermal medication to control post-operative pain associated with surgical procedures in cats.

 

Portfolio

 

Announced Rajeev (Bobby) Modi, as the new Executive Vice President of U.S. Pet Health and Global Digital Transformation, effective March 14.

 

Galliprant®, a product for canine osteoarthritis pain and inflammation, became Elanco's 10th blockbuster brand, registering over $100 million in revenue in 2021.

 

As a part of Elanco's value beyond product strategy in Farm Animal, introduced UpLookTM, an insights engine designed to predict greenhouse gas emissions and identify key drivers of an operation's carbon footprint and became a founding member of the Greener Cattle Initiative, which will focus on reducing enteric methane emissions.

 

Productivity

 

Announced restructuring actions to streamline and simplify organizational structure across marketing, international commercial operations and R&D, including the elimination of approximately 380 positions, with expected savings of approximately $60 million in 2022 and $70 million once fully annualized.

 

Increased expected synergy target from $300 million to $345 million by 2023 and announced an additional $50 million to $60 million of expected savings in 2024 and beyond from the integration of the legacy Bayer Animal Health business into the Elanco ERP system and the streamlining of business processes.

 

Completed the sale of our manufacturing facility in Speke, United Kingdom.

 

2

 

 

Fourth Quarter Reported Results:

 

In the fourth quarter of 2021, revenue was $1,113 million, a decrease of 2 percent, compared with the fourth quarter of 2020. Revenue growth was unfavorably impacted by approximately $60 million of previously disclosed items that benefited the fourth quarter of 2020, including a purchasing shift by a large U.S. pet health customer, a short-term competitor stock-out benefiting our U.S. cattle vaccines and implants business, the exit of certain products and reduced contract manufacturing from the sale of the Shawnee, KS manufacturing facility and discontinued production of human growth hormone for Eli Lilly and Company, our former parent company, at the end of 2020. The business grew in pet health, poultry and aqua, and from innovation-related sales, partially offset by pressure in the China swine business.

 

Pet Health revenue decreased 1 percent for the quarter and was flat when excluding the unfavorable impact from foreign exchange rates. Price growth across the portfolio and volume growth in a number of brands including Credelio®, Galliprant®, Advocate®, vaccines and the addition of innovation products, was more than offset by the impact of competitive pressure on older generation parasiticides and the impact of an approximate $10 million purchasing pattern shift by a large U.S. customer into the fourth quarter of 2020 from the first quarter of 2021. Seresto® and the Advantage® family of products contributed $60 million and $104 million of revenue in the quarter, respectively.

 

Farm Animal revenue decreased 1 percent for the quarter and was flat excluding the unfavorable impact from foreign exchange rates. Performance was driven by growth in global poultry and aqua as a result of improved conditions related to the COVID-19 pandemic and the addition of innovation products, which was more than offset by a decline in the China swine business from pressured producer profitability and the unfavorable impact of exiting certain products since the fourth quarter of 2020 and from a short-term competitor stock-out benefiting our U.S. cattle vaccines and implant business in the fourth quarter of 2020.

 

Contract Manufacturing represents contract manufacturing relationships which are not long-term value drivers for the company. Contract Manufacturing represented 1 percent of total revenue in the quarter and decreased 48 percent compared to the fourth quarter of 2020. The decrease is primarily driven by the impact from the sale of the Shawnee, KS manufacturing site and discontinued production of human growth hormone for Eli Lilly and Company, our former parent company, at the end of 2020.

 

Gross profit was $601 million, or 54.0 percent of revenue, in the fourth quarter of 2021 compared with $544 million, or 47.7 percent, for the fourth quarter of 2020. Gross margin increased 630 basis points, with 500 basis points attributable to the negative impact of the amortization of inventory fair value adjustments recorded from the acquisition of Bayer Animal Health in the fourth quarter of 2020. Further improvement was driven by continued benefits from manufacturing productivity, and improved price and mix, partially offset by increased costs due to inflation.

 

Total operating expense was $421 million, a decrease of $66 million, or 14 percent, compared with the fourth quarter of 2020. Marketing, selling and administrative expenses decreased $45 million to $329 million and research and development expenses decreased $21 million to $92 million, from the realization of synergies associated with restructurings and disciplined cost management.

 

Amortization of intangibles decreased $25 million to $139 million in the fourth quarter of 2021 as compared with the fourth quarter of 2020, primarily from a measurement period adjustment in the first quarter of 2021 that decreased the fair value of intangible assets recorded from the acquisition of Bayer Animal Health. Asset impairment, restructuring, and other special charges decreased to $110 million in the fourth quarter of 2021 from $167 million in the fourth quarter of 2020, primarily due to decreases in integration and acquisition costs and asset impairment and write-down charges, partially offset by an increase in severance costs.

 

Net interest expense was $55 million in the fourth quarter of 2021, compared with $60 million in the fourth quarter of 2020. Tax benefit was $24 million in the fourth quarter of 2021. The fourth quarter of 2021 included a valuation allowance against $40 million of deferred tax assets.

 

Net loss for the fourth quarter of 2021 was $97 million and $0.20 per diluted share, compared with a net loss of $323 million for the same period in 2020.

 

Fourth Quarter Non-GAAP Results:

 

For the fourth quarter of 2021, adjusted gross margin increased 130 basis points to 54.0 percent of revenue, driven by continued improvements in manufacturing productivity, and improved price and mix, partially offset by increased costs due to inflation. Adjusted net income for the fourth quarter increased to $105 million, which excludes the net impact of $202 million of asset impairment, restructuring and other special charges, the amortization of intangible assets and other adjusting items, net of the impact from taxes (including the valuation allowance applied to deferred tax assets). Our adjusted effective tax rate for the fourth quarter was 14.6 percent driven by certain favorable return to provision results. Adjusted EPS in the quarter was $0.21 per share, an increase of 75 percent as compared to the fourth quarter of 2020. Adjusted EBITDA was $212 million in the fourth quarter of 2021, an increase of 20 percent compared to the fourth quarter of 2020. Adjusted EBITDA as a percent of revenue was 19.0 percent compared with 15.4 percent for the fourth quarter of 2020, an improvement of 360 basis points.

 

3

 

 

Full Year Reported Results:

 

For the full year 2021, total revenue was $4,765 million, or an increase of 46 percent over the previous year, including an additional $1,311 million of Bayer Animal Health product revenue in the full year 2021 compared to the full year 2020.

 

Pet Health delivered revenue of $2,351 million, including an additional $855 million of Bayer Animal Health product revenue in the full year 2021 compared to the full year 2020. Results exceeded the company's expectations as many key brands experienced double-digit growth including Credelio, Interceptor® Plus, Advocate, vaccines, and Galliprant, which became a blockbuster in 2021. In parasiticides, the international business delivered strong growth driven by Seresto, Advocate and the Credelio franchise, while the U.S. was impacted by competitive pressures, primarily impacting older generation products.

 

Farm Animal delivered revenue of $2,332 million, including an additional $417 million of Bayer Animal Health product revenue in the full year 2021 compared to the full year 2020. Rumensin® continued to fare better than initial expectations regarding market share despite nearly 2.5 years of generic competition. In the second half of 2021, global poultry and aqua markets benefited from improving economic conditions as the COVID-19 pandemic eased in many markets. These tailwinds were partially offset by pressured producer profitability in the China swine market and the impact of a short-term competitor stock-out benefiting our U.S. cattle vaccines and implant business in the fourth quarter 2020.

 

Contract Manufacturing represented 2 percent of total revenue for the full year 2021 and increased 3 percent compared to the full year 2020. The increase was driven by the addition of $39 million from Bayer Animal Health, offset by the impact of the sale of the Shawnee, KS manufacturing site and discontinued production of human growth hormone for Lilly at the end of 2020.

 

Gross profit was $2,631 million, 55.2 percent of revenue, for the full year 2021, an increase of 610 basis points compared to the full year 2020, primarily due to the benefit from inclusion of the legacy Bayer Animal Health portfolio for the full year, continued improvements in manufacturing productivity, improved price and mix, as well as a favorable comparison to 2020, which was impacted by $26 million higher amortization of inventory fair value adjustments recorded from the acquisition of Bayer Animal Health, partially offset by increased costs due to inflation.

 

Amortization of intangibles increased $196 million to $556 million in 2021 as compared with the full year 2020, primarily due to the inclusion of a full year of amortization of intangible assets recorded from the acquisition of Bayer Animal Health.

 

Asset impairment, restructuring, and other special charges was $628 million in 2021 compared to $623 million in 2020. Charges recorded in 2021 primarily included asset write-downs related to the Shawnee, KS and Speke, United Kingdom manufacturing site sales, costs related to previously announced restructuring activities, transaction costs related to acquisitions, including our acquisition of KindredBio, costs associated with our integration efforts for acquired businesses, including Bayer Animal Health, and asset impairment charges.

 

Tax benefit was $95 million in 2021. Tax benefit in 2021 included a valuation allowance against $42 million of deferred tax assets.

 

Reported net loss and loss per share were $472 million and $0.97, respectively.

 

Full Year Consolidated Non-GAAP Results:

 

For the full year 2021, adjusted gross margin increased 460 basis points to 56.6 percent of revenue primarily due to the benefit from inclusion of the legacy Bayer Animal Health portfolio for the full year, continued improvements in manufacturing productivity, and improved price and mix, partially offset by higher inflation costs. Net income and earnings per share, on a non-GAAP basis, were $514 million and $1.05 per share, respectively. The full year non-GAAP effective tax rate was 22.9 percent for 2021.

 

4

 

 

Adjusted EBITDA was $1,057 million for the full year 2021, which represents 22.2 percent of total revenue compared with 16.1 percent for the full year 2020.

 

Working Capital and Balance Sheet

 

In the fourth quarter, days sales outstanding improved sequentially to 73 days from 81 days in the third quarter of 2021, reflecting improved execution on collections globally. Operating cash flow was $223 million in the fourth quarter of 2021 and $483 million for the full year 2021.

 

As of December 31, 2021, cash and cash equivalents were $638 million, with gross debt of $6,401 million, resulting in net debt of $5,763 million. As of the end of 2021, the company achieved its expected net leverage ratio of 5.5x adjusted EBITDA, while also funding the $444 million purchase price for KindredBio. The company expects to end 2022 with a net leverage ratio of 4.75x adjusted EBITDA.

 

For further detail of non-GAAP measures, see the Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information tables later in this press release.

 

FINANCIAL GUIDANCE

 

Elanco is providing financial guidance for the full year 2022, summarized in the following table:

 

2022 Full Year

(dollars in millions, except per share amounts)

  Guidance 
Revenue  $4,745    to    $4,800 
Reported Net Income  $4    to   $27 
Adjusted EBITDA  $1,140    to   $1,180 
Reported Earnings per Share  $0.01    to   $0.07 
Adjusted Earnings per Share  $1.18    to   $1.24 

 

The company anticipates revenue between $4,745 million and $4,800 million, with a headwind of approximately $95 million from the unfavorable impact for foreign exchange rates this year. Growth is expected to be driven by newly launched innovation products, increased price across the portfolio, and growth in key focus brands, partially offset by lower revenue as a result of competitive pressure in the U.S. pet health parasiticides market, headwinds in the China swine business and the reduction of contract manufacturing revenue.

 

Additionally, Elanco is providing financial guidance for the first quarter of 2022, summarized in the following table:

 

2022 First Quarter

(dollars in millions, except per share amounts)

  Guidance 
Revenue  $1,200    to   $1,230 
Reported Net Income  $7    to   $33 
Adjusted EBITDA  $310    to   $340 
Reported Earnings per Share  $0.01    to   $0.07 
Adjusted Earnings per Share  $0.33    to   $0.38 

 

The company expects revenue between $1,200 million and $1,230 million. Growth is expected to be driven by key focus brands and innovation products, offset by continued headwinds in the China swine business and the reduction of contract manufacturing revenue.

 

The financial guidance reflects foreign exchange rates as of the beginning of February. Further details on guidance, including GAAP reported to non-GAAP adjusted reconciliations, are included in the financial tables of this press release and will be discussed on the company's conference call this morning.

 

WEBCAST & CONFERENCE CALL DETAILS

 

Elanco will host a webcast and conference call at 8:00 a.m. Eastern Time today, during which company executives will review fourth quarter and full year 2021 financial and operational results, provide financial guidance for the full year and first quarter of 2022, and respond to questions from analysts. Investors, analysts, members of the media and the public may access the live webcast and accompanying slides by visiting the Elanco website at https://investor.elanco.com and selecting Events and Presentations. A replay of the webcast will be archived and made available a few hours after the event on the company's website, at https://investor.elanco.com/investor/events-and-presentations.

 

5

 

 

ABOUT ELANCO

 

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability/ESG framework – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 , including, without limitation, statements concerning expected synergies and cost savings, product launches and revenue from such products, cost savings and expenses relating to restructuring actions, the impact of the COVID-19 pandemic and related disruptions on our business, our 2022 full year and first quarter guidance and long-term expectations, our expectations regarding debt levels, our industry and our operations, performance and financial condition, and including, in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses.

 

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national, or global political, economic, business, competitive, market, and regulatory conditions, including but not limited to the following:

 

heightened competition, including from generics;

 

the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein;

 

changes in regulatory restrictions on the use of antibiotics in farm animals;

 

our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements;

 

consolidation of our customers and distributors;

 

an outbreak of infectious disease carried by farm animals;

 

the impact on our operations, the supply chain, customer demand, and our liquidity as a result of the COVID-19 global health pandemic;

 

the success of our R&D and licensing efforts;

 

misuse, off-label or counterfeiting use of our products;

 

unanticipated safety, quality or efficacy concerns and the impact of identified concerns associated with our products;

 

fluctuations in our business results due to seasonality and other factors;

 

the impact of weather conditions and the availability of natural resources;

 

risks related to the modification of foreign trade policy;

 

risks related to currency rate fluctuations;

 

our dependence on the success of our top products;

 

the impact of customer exposure to rising costs and reduced customer income and the lack of availability or significant increases in the cost of raw materials;

 

6

 

 

use of alternative distribution channels and the impact of increased or decreased sales to our channel distributors resulting in fluctuation in our revenues;

 

risks related to the write down of goodwill or identifiable intangible assets;

 

risks related to the evaluation of animals;

 

manufacturing problems and capacity imbalances;

 

the impact of litigation, regulatory investigations, and other legal matters and the risk that our insurance policies may be insufficient to protect us from the impact of such matters;

 

actions by regulatory bodies, including as a result of their interpretation of studies on product safety;

 

risks related to tax expense or exposure;

 

risks related to environmental, health and safety laws and regulations;

 

risks related to our presence in foreign markets;

 

challenges to our intellectual property rights or our alleged violation of rights of others;

 

our dependence on sophisticated information technology and infrastructure and impact of breaches of our information technology systems;

 

the impact of increased regulation or decreased financial support related to farm animals;

 

adverse effects of labor disputes, strikes, work stoppages, and the loss of key personnel or highly skilled employees;

 

risks related to underfunded pension plan liabilities;

 

our ability to complete acquisitions and successfully integrate the businesses we acquire, including KindredBio and the animal health business of Bayer (Bayer Animal Health);

 

the effect of our substantial indebtedness on our business, including restrictions in our debt agreements that will limit our operating flexibility; and

 

risks related to certain governance provisions in our constituent documents.

 

For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company’s latest Form 10-K and subsequent Form 10-Qs filed with the Securities and Exchange Commission. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this press release. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this press release. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should be viewed as historical data.

 

Use of Non-GAAP Financial Measures:

 

We use non-GAAP financial measures, such as revenue excluding the impact of foreign exchange rate effects, adjusted constant currency revenue growth, EBITDA, EBITDA margin, adjusted EBITDA, adjusted EBITDA margin, adjusted net (income) loss, adjusted EPS, adjusted gross profit and adjusted gross margin and net debt leverage to assess and analyze our operational results and trends as explained in more detail in the reconciliation tables later in this release.

 

7

 

 

We believe these non-GAAP financial measures are useful to investors because they provide greater transparency regarding our operating performance. Reconciliation of non-GAAP financial measures and reported GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.elanco.com. The primary material limitations associated with the use of such non-GAAP measures as compared to U.S. GAAP results include the following: (i) they may not be comparable to similarly titled measures used by other companies, including those in our industry, (ii) they exclude financial information and events, such as the effects of an acquisition or amortization of intangible assets, that some may consider important in evaluating our performance, value or prospects for the future, (iii) they exclude items or types of items that may continue to occur from period to period in the future and (iv) they may not exclude all unusual or non-recurring items, which could increase or decrease these measures, which investors may consider to be unrelated to our long-term operations. These non-GAAP measures are not, and should not be viewed as, substitutes for U.S. GAAP reported measures. We encourage investors to review our unaudited condensed consolidated and combined financial statements in their entirety and caution investors to use U.S. GAAP measures as the primary means of evaluating our performance, value and prospects for the future, and non-GAAP measures as supplemental measures.

 

Availability of Certain Information

 

We use our website to disclose important company information to investors, customers, employees and others interested in Elanco. We encourage investors to consult our website regularly for important information about Elanco.

 

8

 

 

Elanco Animal Health Incorporated

Unaudited Consolidated Statements of Operations

(Dollars and shares in millions, except per share data)

 

   Three Months Ended
December 31,
   For the year Ended
December 31,
 
   2021   2020   2021   2020 
Revenue  $1,113   $1,140   $4,765   $3,273 
Costs, expenses, and other:                    
Cost of sales   512    596    2,134    1,667 
Research and development   92    113    369    327 
Marketing, selling, and administrative   329    374    1,404    996 
Amortization of intangible assets   139    164    556    360 
Asset impairment, restructuring, and other special charges   110    167    628    623 
Interest expense, net of capitalized interest   55    60    236    150 
Other (income) expense, net   (3)   (16)   5    (178)
Loss before income taxes  $(121)  $(318)  $(567)  $(672)
Income tax expense (benefit)   (24)   5    (95)   (112)
Net Loss  $(97)  $(323)  $(472)  $(560)
Loss per share:                    
Basic  $(0.20)  $(0.66)  $(0.97)  $(1.27)
Diluted  $(0.20)  $(0.66)  $(0.97)  $(1.27)
Weighted average shares outstanding:                    
Basic   487.4    486.2    487.2    441.4 
Diluted   487.4    486.2    487.2    441.4 

 

9

 

 

Elanco Animal Health Incorporated

Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information

(Unaudited)

(Dollars and shares in millions, except per share data)

 

We define adjusted gross profit as total revenue less adjusted cost of sales and adjusted gross margin as adjusted gross profit divided by total revenue.

 

We define adjusted net income as net income (loss) excluding amortization of intangible assets, purchase accounting adjustments to inventory, integration costs of acquisitions, severance, asset impairment, gain on sale of assets, facility exit costs, tax valuation allowances and other specified significant items, such as unusual or non-recurring items that are unrelated to our long-term operations adjusted for income tax expense associated with the excluded financial items.

 

We define adjusted EBITDA as net income (loss) adjusted for interest expense (income), income tax expense (benefit), tax valuation allowances, and depreciation and amortization, further adjusted to exclude purchase accounting adjustments to inventory, integration costs of acquisitions, severance, asset impairment, gain on sale of assets, facility exit costs and other specified significant items, such as unusual or non-recurring items that are unrelated to our long-term operations adjusted for income tax expense associated with the excluded financial items.

 

We define adjusted EPS as adjusted net income divided by the number of weighted average shares outstanding as of December 31, 2021 and 2020.

 

We define net debt as gross debt less cash and cash equivalents on the balance sheet. We define gross debt as the sum of the current portion of long-term debt and long-term debt excluding unamortized debt issuance costs. We define the net leverage ratio as gross debt less cash and cash equivalents divided by adjusted EBITDA. This calculation does not include Term Loan B covenant-related adjustments that reduce this leverage ratio.

 

The following is a reconciliation of revenue growth for the fourth quarter of 2021:

 

   Change (%) 
Reported Revenue Growth (Decline)   (2)%
Impact of previously disclosed items affecting comparability (1)   5%
Impact of foreign exchange rates   1%
Adjusted Constant Currency Growth   4%

 

(1) Previously disclosed items affecting comparability include $10 million from a purchasing shift by a large U.S. pet health customer, $10 million from a short-term competitor stock-out benefiting our U.S. cattle vaccines and implants business, $20 million from the exit of certain products and $20 million from reduced contract manufacturing from the sale of the Shawnee, KS manufacturing facility and discontinued production of human growth hormone for Eli Lilly and Company, our former parent company, at the end of 2020.

 

10

 

 

The following is a reconciliation of GAAP reported for the three months ended December 31, 2021 and 2020 to selected non-GAAP adjusted information:

 

   2021   2020 
   GAAP
Reported
   Adjusted
Items (b)
   Non-
GAAP (a)
   GAAP
Reported
   Adjusted
Items (b)
   Non-
GAAP (a)
 
Cost of sales (1)   $512   $   $512   $596   $57   $539 
Amortization of intangible assets  $139   $139   $   $164    164   $ 
Asset impairment, restructuring and other special charges (2) (3)  $110   $110   $   $167   $167   $ 
Other (income) expense, net (4) (5)  $(3)  $(5)  $2   $(16)  $(2)  $(14)
Income (loss) before taxes  $(121)  $244   $123   $(318)  $386   $68 
Provision for taxes (6) (7)  $(24)  $(42)  $18   $5   $(6)  $11 
Net income (loss)  $(97)  $202   $105   $(323)  $380   $57 
Earnings (loss) per share:                              
basic  $(0.20)  $0.41   $0.22   $(0.66)  $0.78   $0.12 
diluted  $(0.20)  $0.41   $0.21   $(0.66)  $0.78   $0.12 
Adjusted weighted average shares outstanding:                              
basic   487.4    487.4    487.4    486.2    486.2    486.2 
diluted (8)   487.4    489.8    489.8    486.2    488.2    488.2 

 

Numbers may not add due to rounding.

 

The table above reflects only line items with non-GAAP adjustments.

 

(a)The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company’s ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.

 

(b)Adjustments to certain GAAP reported measures for the three months ended December 31, 2021 and 2020 include the following:

 

(1)2020 excludes amortization of inventory fair value adjustments recorded from the acquisition of Bayer Animal Health ($57 million).

 

(2)2021 excludes charges associated with integration efforts and external costs related to the acquisitions of Bayer Animal Health and KindredBio ($21 million), severance ($85 million), asset impairments ($3 million), and asset write-downs ($2 million), and the settlement of a legal matter ($2 million), partially offset by curtailment gains recognized due to the remeasurement our pension benefit obligations resulting from workforce reductions associated with our recent restructuring programs ($2 million).

 

(3)2020 excludes charges associated with integration efforts and external costs related to the acquisition of businesses, including the acquisition of the animal health business of Bayer, and charges primarily related to independent stand-up costs and other related activities ($106 million), severance ($24 million), asset impairments ($14 million), facility exit costs and asset write-downs ($12 million), a one-time expense associated with our agreement to build a new corporate headquarters ($9 million), registration fees for Elanco common shares sold by Bayer AG during the quarter ($1 million), and a payment for acquired IPR&D from a collaboration arrangement ($1 million).

 

(4)2021 excludes the gain recorded on the sale of certain equine assets ($4 million) and the impact of a decrease in the fair value of the Prevtec contingent consideration ($1 million).

 

(5)2020 excludes the impact of a decrease in the fair value of the Prevtec contingent consideration ($2 million).

 

11

 

 

(6)2021 represents the income tax expense associated with the adjusted items, partially offset by the impact of the valuation allowance recorded against our deferred tax assets during the period ($40 million).

 

(7)2020 represents the income tax expense associated with the adjusted items, partially offset by the impact of the valuation allowance recorded against our U.S. deferred tax assets during the period ($75 million).

 

(8)During the three months ended December 31, 2021 and 2020, we reported a GAAP net loss and thus potential dilutive common shares were not assumed to have been issued since their effect is anti-dilutive. During the same period, we reported non-GAAP net income. As a result, potential dilutive common shares would not have an anti-dilutive effect, and diluted weighted average shares outstanding for purposes of calculating Adjusted EPS include 2.4 million and 2.0 million, respectively, of common stock equivalents.

 

   Q4 2021   Q4 2020 
As Reported EPS  $(0.20)  $(0.66)
Cost of sales       0.12 
Amortization of intangible assets   0.28    0.34 
Asset impairment, restructuring and other special charges   0.22    0.34 
Other (income) expense, net   (0.01)   0.00 
Subtotal   0.50    0.79 
Tax Impact of Adjustments (1) (2)   (0.09)   (0.01)
Total Adjustments to EPS  $0.41   $0.78 
           
Adjusted EPS (3)  $0.21   $0.12 

 

Numbers may not add due to rounding.

 

(1) 2021 includes the favorable adjustment relating to the valuation allowance recorded against our deferred tax assets during the fourth quarter of 2021 (impact of $0.08 per share).

 

(2) 2020 includes the favorable adjustment relating to the valuation allowance recorded against our U.S. deferred tax assets during the fourth quarter of 2020 (impact of $0.15 per share).

 

(3) Adjusted EPS is calculated as the sum of As Reported EPS and Total Adjustments to EPS.

 

12

 

 

The following is a reconciliation of GAAP Reported for the year ended December 31, 2021 and 2020 to Selected Non-GAAP Adjusted information:

 

   2021   2020 
   GAAP
Reported
   Adjusted
Items (b)
   Non-
GAAP (a)
   GAAP
Reported
   Adjusted
Items (b)
   Non-
GAAP (a)
 
Cost of sales (1) (2)  $2,134   $64   $2,070   $1,667   $96   $1,571 
Amortization of intangible assets  $556   $556   $   $360   $360   $ 
Asset impairment, restructuring and other special charges (3) (4)  $628   $628   $   $623   $623   $ 
Interest expense, net of capitalized interest (5)  $236   $   $236   $150   $3   $147 
Other (income) expense, net (6) (7)  $5   $(14)  $19   $(178)  $(168)  $(10)
Income (loss) before taxes  $(567)  $1,234   $667   $(672)  $914   $242 
Provision for taxes (8) (9)  $(95)  $(248)  $153   $(112)  $(147)  $35 
Net income (loss)  $(472)  $986   $514   $(560)  $767   $207 
Earnings (loss) per share:                              
basic  $(0.97)  $2.02   $1.06   $(1.27)  $1.74   $0.47 
diluted  $(0.97)  $2.02   $1.05   $(1.27)  $1.74   $0.47 
Adjusted weighted average shares outstanding:                              
basic   487.2    487.2    487.2    441.4    441.4    441.4 
diluted (10)   487.2    488.9    488.9    441.4    442.6    442.6 

 

Numbers may not add due to rounding.

 

The table above reflects only line items with non-GAAP adjustments.

 

(a)The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company’s ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.

 

(b)Adjustments to certain GAAP reported measures for the year ended December 31, 2021 and 2020 include the following:

 

(1)2021 excludes amortization of inventory fair value adjustments recorded from the acquisition of Bayer Animal Health ($64 million).

 

(2)2020 excludes amortization of inventory fair value adjustments recorded from the acquisition of Bayer Animal Health ($90 million), charges associated with the write-off of marketing inventory recorded from the acquisition of Bayer Animal Health ($2 million), and a one-time payment to settle outstanding obligations to a contract manufacturing organization in connection with a divestiture ($4 million).

 

(3)2021 excludes charges associated with integration efforts and external costs related to the acquisitions of Bayer Animal Health and KindredBio, and charges primarily related to independent stand-up costs and other related activities ($162 million), a charge associated with the settlement of a liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio ($26 million), costs associated with the sale of our manufacturing sites in Shawnee, Kansas and Speke, U.K. and other business development transactions ($5 million), severance accruals net of reversals ($110 million), asset impairments ($66 million), asset write-downs ($278 million), and the settlement of legal matters ($10 million), partially offset by curtailment gains recognized due to the remeasurement our pension benefit obligations resulting from workforce reductions associated with our recent restructuring programs ($29 million).

 

13

 

 

(4)2020 excludes charges associated with integration efforts and external costs related to the acquisition of businesses, including the acquisition of the animal health business of Bayer, and charges primarily related to independent stand-up costs and other related activities ($424 million), severance accruals net of reversals ($155 million), asset impairments ($17 million), facility exit costs and asset write-downs ($17 million), a one-time payment associated with our agreement to build a new corporate headquarters ($9 million), the settlement of a legal matter ($3 million), registration fees for Elanco common shares sold by Bayer AG during the quarter ($1 million), and a payment for acquired IPR&D from a collaboration arrangement ($1 million), partially offset by adjustments to write-downs of assets held for sale ($1 million) and the gain on the sale of our R&D facility in Prince Edward Island, Canada ($4 million).

 

(5)2020 excludes the debt extinguishment losses recorded in connection with the repayments of our existing term loan facilities ($3 million).

 

(6)2021 excludes up-front payments received and equity issued to us in relation to license and asset assignment agreements ($9 million), the gain recorded on the sale of certain equine assets ($4 million), and the impact of a decrease in the fair value of the Prevtec contingent consideration ($1 million).

 

(7)2020 excludes the gains recorded in relation to the divestiture of several products as required as a result of the acquisition of the animal health business of Bayer ($157 million), a hedging gain related to the closing of the acquisition of the animal health business of Bayer ($6 million), the gain on our sale of land and buildings in New South Wales, Australia ($45 million) and the impact of a decrease in the fair value of the Prevtec contingent consideration ($4 million), partially offset by financing commitment and advisory fees associated with the Bayer Animal Health acquisition ($36 million) and a loss recorded in relation to the divestiture of products ($7 million).

 

(8)2021 represents the income tax expense associated with the adjusted items, partially offset by a net increase in the valuation allowance recorded against our deferred tax assets during the period ($42 million).

 

(9)2020 represents the income tax expense associated with the adjusted items, partially offset by the impact of the valuation allowance recorded against our U.S. deferred tax assets during the period ($75 million).

 

(10)During the year ended December 31, 2021 and 2020, we reported a GAAP net loss and thus potential dilutive common shares were not assumed to have been issued since their effect is anti-dilutive. During the same period, we reported non-GAAP net income. As a result, potential dilutive common shares would not have an anti-dilutive effect, and diluted weighted average shares outstanding for purposes of calculating Adjusted EPS include 1.7 million and 1.2 million, respectively, of common stock equivalents.

 

   Year-to-date 
   2021   2020 
As Reported EPS  $(0.97)  $(1.27)
Cost of sales   0.13    0.22 
Amortization of intangible assets   1.14    0.82 
Asset impairment, restructuring and other special charges   1.28    1.41 
Interest expense, net of capitalized interest       0.01 
Other (income) expense, net   (0.03)   (0.38)
Subtotal  $2.52   $2.07 
Tax Impact of Adjustments (1) (2)   (0.51)   (0.33)
Total Adjustments to EPS  $2.02   $1.74 
           
Adjusted EPS (3)  $1.05   $0.47 

 

Numbers may not add due to rounding.

 

(1) 2021 includes the favorable adjustment relating to the valuation allowance recorded against our deferred tax assets during the fourth quarter of 2021 (impact of $0.09 per share).

 

(2) 2020 includes the favorable adjustment relating to the valuation allowance recorded against our U.S. deferred tax assets during the fourth quarter of 2020 (impact of $0.17 per share).

 

(3) Adjusted EPS is calculated as the sum of As Reported EPS and Total Adjustments to EPS.

 

14

 

 

For the periods presented, we have not made adjustments for all items that may be considered unrelated to our long-term operations. We believe adjusted EBITDA, when used in conjunction with our results presented in accordance with U.S. GAAP and its reconciliation to net income, enhances investors' understanding of our performance, valuation and prospects for the future. We also believe adjusted EBITDA is a measure used in the animal health industry by analysts as a valuable performance metric for investors.

 

The following is a reconciliation of U.S. GAAP Net Income for the three months ended and for the year ended December 31, 2021 and 2020 to EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin, which is Adjusted EBITDA divided by total Revenue, for the respective periods:

 

   Three Months Ended December 31,   Year Ended December 31, 
   2021   2020   2021   2020 
Reported net loss  $(97)  $(323)  $(472)  $(560)
Net interest expense   55    60    236    150 
Income tax expense (benefit)   (24)   5    (95)   (112)
Depreciation and amortization   174    222    716    517 
EBITDA  $108   $(36)  $385   $(5)
Non-GAAP Adjustments:                    
Cost of sales  $   $57   $64   $96 
Asset impairment, restructuring and other special charges   110    167    628    623 
Accelerated depreciation(1)   (1)   (11)   (6)   (17)
Other income, net   (5)   (2)   (14)   (168)
Adjusted EBITDA  $212   $176   $1,057   $529 
Adjusted EBITDA Margin   19.0%   15.4%   22.2%   16.1%

 

Numbers may not add due to rounding.

 

(1) Represents depreciation of certain assets that was accelerated during the periods presented. This amount must be added back to arrive at Adjusted EBITDA because it is included in Asset impairment, restructuring, and other special charges but it has already been excluded from EBITDA in the "Depreciation and amortization" row above.

 

The following is a reconciliation of gross debt to net debt for the year ended December 31, 2021:

 

     
Long-term debt  $6,258 
Current portion of long-term debt   61 
Less: Unamortized debt issuance costs   (82)
Total gross debt   6,401 
Less: Cash and cash equivalents   638 
Net Debt  $5,763 

 

15

 

 

Elanco Animal Health Incorporated

2022 Full Year and First Quarter Guidance

 

Reconciliation of 2022 full year reported EPS guidance to 2022 adjusted EPS guidance is as follows:

 

   Full Year 2022 Guidance 
Reported Earnings per Share  $0.01   to  $0.07 
Amortization of Intangible Assets       $1.11     
Asset Impairment, Restructuring, and Other Special Charges(1)  $0.39   to  $0.43 
Subtotal  $1.50   to  $1.54 
Tax Impact of Adjustments  $(0.33)  to  $(0.37)
Total Adjustments to Earnings per Share       $1.17     
Adjusted Earnings per Share(2)  $1.18   to  $1.24 

 

Numbers may not add due to rounding.

 

(1)  Asset impairment, restructuring, and other special charges adjustments primarily relate to integration efforts of acquired businesses, including the animal health business of Bayer, and other related activities.

 

(2) Adjusted EPS is calculated as the sum of reported EPS and total adjustments to EPS.

 

Reconciliation of 2022 reported net income (loss) to 2022 adjusted EBITDA guidance is as follows:

 

$ millions  Full Year 2022 Guidance 
Reported Net Income  $4   to  $27 
Net Interest Expense       Approx. $220     
Income Tax Expense  $4   to  $26 
Depreciation and Amortization       Approx. $735     
EBITDA  $953   to  $1,012 
Non-GAAP Adjustments             
Asset Impairment, Restructuring, and Other Special Charges       Approx. $205     
Accelerated Depreciation & Other Special Charges      Approx. $(30)     
Adjusted EBITDA  $1,140   to  $1,180 
Adjusted EBITDA Margin   24.0%  to   24.6%

 

Numbers may not add due to rounding.

 

Reconciliation of 2022 first quarter reported EPS guidance to 2022 first quarter adjusted EPS guidance is as follows:

 

   First Quarter 2022 Guidance 
Reported Earnings per Share  $0.01   to  $0.07 
Amortization of Intangible Assets       $0.28     
Asset Impairment, Restructuring, and Other Special Charges(1)  $0.09   to  $0.12 
Subtotal  $0.36   to  $0.40 
Tax Impact of Adjustments  $(0.05)  to  $(0.09)
Total Adjustments to Earnings per Share  $0.31   to  $0.32 
Adjusted Earnings per Share(2)  $0.33   to  $0.38 

 

Numbers may not add due to rounding.

 

(1) Asset impairment, restructuring, and other special charges adjustments primarily relate to integration efforts of acquired businesses, including the animal health business of Bayer, and other related activities.

 

(2) Adjusted EPS is calculated as the sum of reported ESP and total adjustments to EPS.

 

16

 

 

Reconciliation of 2022 first quarter reported net income (loss) to 2022 first quarter adjusted EBITDA guidance is as follows:

 

$ millions  First Quarter 2022 Guidance 
Reported Net Income  $7   to  $33 
Net Interest Expense       Approx. $55     
Income Tax Expense  $7   to  $32 
Depreciation and Amortization       Approx. $185     
EBITDA  $255   to  $305 
Non-GAAP Adjustments             
Asset Impairment, Restructuring, and Other Special Charges       Approx. $55     
Accelerated Depreciation & Other Special Charges       Approx. $(7)     
Adjusted EBITDA  $310   to  $340 
Adjusted EBITDA Margin   26.0%  to   27.7%

 

Numbers may not add due to rounding.

 

The table below provides a breakdown of revenue by species and the respective percent of total revenue for the same period (in millions, except percentages):

 

   Three Months Ended December 31, 2021   Year Ended
December 31, 2021
 
Pet Health  $494    44%  $2,351    49%
Farm Animal                    
Cattle   254    23%   1,008    21%
Poultry   199    18%   716    15%
Swine   118    11%   464    10%
Aqua   33    3%   144    3%
Total Farm Animal  $604    54%  $2,332    49%
Revenue Subtotal  $1,098        $4,683      
Contract Manufacturing   15    1%   82    2%
Total Revenue  $1,113    100%  $4,765    100%

 

Numbers may not add due to rounding.

 

17

EX-101.SCH 4 elan-20220222.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 elan-20220222_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 elan-20220222_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Equity Components [Axis] Common Stock [Member] 5.00 Percent Tangible Equity Units [Member] Statement [Table] Entity Listings [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] 5.00 Percent Tangible Equity Units Respectively. 5.00 Percent Tangible Equity Units Respectively. EX-101.PRE 7 elan-20220222_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 tm227491d1_ex99-1img001.jpg GRAPHIC begin 644 tm227491d1_ex99-1img001.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover
Feb. 22, 2022
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 22, 2022
Current Fiscal Year End Date --12-31
Entity File Number 001-38661
Entity Registrant Name Elanco Animal Health Incorporated
Entity Central Index Key 0001739104
Entity Tax Identification Number 82-5497352
Entity Incorporation, State or Country Code IN
Entity Address, Address Line One 2500 Innovation Way
Entity Address, City or Town Greenfield
Entity Address, State or Province IN
Entity Address, Postal Zip Code 46140
City Area Code 877
Local Phone Number 352-6261
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common stock, no par value
Trading Symbol ELAN
Security Exchange Name NYSE
5.00 Percent Tangible Equity Units [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 5.00% Tangible Equity Units
Trading Symbol ELAT
Security Exchange Name NYSE
XML 10 tm227491d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001739104 2022-02-22 2022-02-22 0001739104 us-gaap:CommonStockMember 2022-02-22 2022-02-22 0001739104 elan:TangiblePercentEquityUnitsMember 2022-02-22 2022-02-22 iso4217:USD shares iso4217:USD shares 0001739104 false --12-31 8-K 2022-02-22 Elanco Animal Health Incorporated IN 001-38661 82-5497352 2500 Innovation Way Greenfield IN 46140 877 352-6261 false false false false Common stock, no par value ELAN NYSE 5.00% Tangible Equity Units ELAT NYSE false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .PS6%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #L,UA4'@,_:.T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OITG%0^CVLN))07!!\1:2V=U@TX1DI-VW-XV[740?P&-F_GSS M#4RG@]0^XG/T 2-93#>S&\8D==BP(U&0 $D?T:E4Y\28FWL?G:+\C <(2G^H M X)HFCMP2,HH4K J[ 26=\9+75$13Z>\4:O^/ 9AP(S&G! AR,EX#4'UB\3 MPVD>.K@"%AAA=.F[@&8EENJ?V-(!=D[.R:ZI:9KJJ2VYO .'MZ?'E[)N9<=$ M:M28?R4KZ11PPRZ37]OM_>Z!]:(1HFI$)6YWG,N62R'>%]&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M[#-85(.5VQK ! *!0 !@ !X;"]W;W)K'Q^_Q\GE6NEGL^3:JL;1V]<'S3+3D*3/G M:L4E_#)7.F463O7",RO-69P'I8E'?;_CI4S(1O\ROS;6_4N5V41(/M;$9&G* M].:&)VI]U0@:^PN/8K&T[H+7OURQ!9]P^VTUUG#F%2JQ2+DT0DFB^?RJ<1U\ MN FI"\CO^%/PM3DX)FXH,Z6>W1&R75XU>@\1\SK+$/JKU9[X;4-OI12HQ^2=9 M;^]MM1HDRHQ5Z2X8"%(AM]_L=9>(@X#P6 #=!>2)\+9_E%-^9);U+[5:$^WN M!C5WD \UCP8X(=VL3*R&7P7$V?Y O7!]Z5F0\:!=VLPVC1\)N^>R<4'I& MJ$_IO\,]("@P:(%!<[WPB-Y06F$WY$X8*^3"D!]W< ,969Z:OQ'YL) /<_G6 M$?F/*LJ@E"R9;E:\:K1X>*_Y!8%H%1 M5.4:".*OWM74P>=@JV#*@XRK?,,"1.QA'SG3*-\ MN%JS&=!F&"!LW@&KX?-,->IX/Q] J>WBD\CWP! M*T8SR-@#2RLS5*.3,!FI]]=2I)#NSYPE=DE&<$FOE(:^J:+%E7Q(83>\"/P6@A7XI?7YIX!-V2L9Q4 GYB)B>:\X/L4U MDCW:;+MG.QQ/;8*AE&PAP(W^+.G!G MD,BI6LM*3%SND^9-ETIB3:)&!*RCV:%HDPC*+A'@]OZDA;5<0F+2-),[=S.55+A0W=XC*)M! M@'OX1"4B$FZ71^ZAO+5@224/KE+'0\LF0''''FO>C" ]'-;7=HL(NS2NR=?Y MO'K^:O1JR4KSI[@]_X=L9$P&9+6 N&PMX,&>_23C'Z9<+]Q\?@(%V#Y L:V8 MK&SO-8*U:*714]R97<%#WYA8%3V3'_?<+4;L08*6)DU;O^))A9962W%CG H+ MFTPU)P']??8'F? H@U5RF M?;))9ZIR$=<(#.^NL>Y$2^.EN&?NP@8'GJRAW%$ 2,YC4X<_,47Z3PIJ3JK)T57KQ2YZ?2YL,<5O['U59H^12 M\UMU3C#2TC9#W-_JR[)& ,IRBI&4_ACB=G9Z6=8('2M+[^"]CWN'=L^<$1N2 M\#GH^.==\ >]?2VU/;%JE;\*FBEK59H?+CF#;N)N@-_G2MG]B7N[5+P<[/\# M4$L#!!0 ( .PS6%2?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8Q MYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_* M%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2 M,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T] M.PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D M'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3 M\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_R MBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P M6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8 MLAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z M'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8 M"<:1/,<0F,7XC&894IT,/O'^8* \^ M>Q\ETWLJ.?]74_P$4$L#!!0 ( .PS6%27BKL

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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 3 122 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://elanco.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm227491d1_8k.htm elan-20220222.xsd elan-20220222_def.xml elan-20220222_lab.xml elan-20220222_pre.xml tm227491d1_ex3-1.htm tm227491d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm227491d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "elan-20220222_def.xml" ] }, "inline": { "local": [ "tm227491d1_8k.htm" ] }, "labelLink": { "local": [ "elan-20220222_lab.xml" ] }, "presentationLink": { "local": [ "elan-20220222_pre.xml" ] }, "schema": { "local": [ "elan-20220222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 1, "memberStandard": 1, "nsprefix": "elan", "nsuri": "http://elanco.com/20220222", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm227491d1_8k.htm", "contextRef": "From2022-02-22to2022-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://elanco.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm227491d1_8k.htm", "contextRef": "From2022-02-22to2022-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "booleanItemType" }, "elan_TangiblePercentEquityUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.00 Percent Tangible Equity Units Respectively.", "label": "5.00 Percent Tangible Equity Units [Member]" } } }, "localname": "TangiblePercentEquityUnitsMember", "nsuri": "http://elanco.com/20220222", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [], "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://elanco.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001104659-22-026319-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-026319-xbrl.zip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end